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ABSTRACT

The endocannabinoid system and CB1 and CB2 cannabinoid receptors have
been implicated in cardiac remodeling with CB1 inhibition and CB2 activation reported
to be beneficial. However, the role of these receptors in cardiac remodeling secondary
to hypertension is not known. Moreover, the functions of the CB1 and CB2 cannabinoid
receptors in cardiac ventricular fibroblasts and their downstream fibrotic pathways have
not yet been elucidated. This study was designed to determine the temporal myocardial
expression pattern of CB1 and CB2 receptors in cardiac remodeling secondary to
pressure overload (PO) induced hypertension at 3, 5, 14 and 28 days. The expression
of the cannabinoid CB1 and CB2 receptors on human ventricular fibroblasts and the
effects of their direct modulation on the fibrotic responses were also investigated. Rat
model of pressure overload induced by abdominal aortic constriction was used for the in
vivo study while the human ventricular fibroblast cell line was used for the in vitro study.
The presence of CB1 and CB2 receptors was demonstrated on rat fibroblasts in left
ventricular cross-sections and on human ventricular fibroblasts for the first time.
Myocardial CB1 receptor levels were transiently increased at 3 days before showing
decreased expression at the 14 and 28 day time points in the PO groups as compared
to sham values. Myocardial CB2 receptor levels were significantly increased at the 3, 5
and 14 day time points in the PO groups as compared to sham values. Thus, the
endocannabinoid system was found to be responsive to the pathophysiological changes
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occurring in cardiac remodeling secondary to pressure overload with temporal
alterations in the expression of cannabinoid receptors. CB1 receptor antagonism on
human ventricular fibroblasts was found to decrease their collagen expression and
production, thus having an anti-fibrotic effect while CB2 receptor antagonism was found
to promote their collagen expression and production, thus having a profibrotic effect.
Thus, CB1 antagonism and CB2 agonism seem to be involved in mediating a protective
effect against fibrotic responses of the human ventricular fibroblasts. Modulation of
these receptors could thus offer an exciting new avenue for development of anti-fibrotic
therapies and attenuating adverse remodeling changes.
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INTRODUCTION

Cardiac Remodeling
Remodeling of the heart involves molecular, cellular and interstitial changes,
which result in alteration of the structure and function of the ventricles in response to
physiological and pathological stimuli. Depending on the etiology, cardiac remodeling
consists of myocyte hypertrophy, myocyte necrosis or apoptosis, formation of infarct,
changes in left ventricular chamber size, increased collagen production and deposition
in the extracellular matrix (ECM) (also termed as fibrosis) and changes in the coronary
vasculature. These changes progressively increase the workload of the heart making it
susceptible to failure over a period of time. Pathological stimuli, which induce
remodeling, include cardiac injury [ischemia, infarction, inflammatory heart muscle
disease (myocarditis), idiopathic dilated cardiomyopathy], pressure overload
(hypertension, aortic stenosis) and volume overload (valvular regurgitation) (Takano et
al., 2003; Fedak et al., 2005a, 2005b).
Pathological remodeling can be divided into two stages: adaptive and
maladaptive. Stimuli such as hypertension or aortic stenosis increase the afterload of
the heart. Adaptive remodeling helps to maintain a normal cardiac output by the heart
against an increased afterload to ensure adequate blood flow to all the organs of the
1

body. Cardiac output is defined as the amount of blood pumped by the heart in 1 minute
(about 5 liters/min, average value for resting adult) (Guyton and Hall, 2010, pg. 229)
and afterload is the load or pressure against which the heart has to pump out the blood
from the ventricle (Guyton and Hall, 2010, pg. 109). However after the adaptive stage,
when the stimuli persist, the hypertrophy and changes in the ECM lead to increased
thickness and stiffness of the ventricular walls. This leads to decreased contractility and
inability of the left ventricle to maintain the required cardiac output eventually
predisposing it to failure over a period of time. This type of remodeling is classified
under the maladaptive stage.

Hypertension
Chronic hypertension is one of the major causes of remodeling of the heart.
Hypertension is a highly prevalent disorder in today’s age with a worldwide incidence of
around 40% in adults aged 25 and over, according to a World Health Organization
(WHO) report in the year 2008 (Global Health Observatory- Raised Blood Pressure,
2013). In the United States, 1 out of every 3 adults (e.g. about 78 million people) has
high blood pressure (Go et al., 2013) and as per statistics from NHANES 2011–12, of
those with hypertension, 83 % are aware of their condition, 76 % are under current
treatment, 52 % have it controlled and 48 % do not have it controlled [Nwankwo et al.,
2013]. The number of people affected by hypertension is increasing every year and the
current therapies are only partially beneficial at preventing or reversing the adverse
remodeling changes affecting cardiac function (Gustafsson et al., 2010). Thus, there is
2

a need for improved therapies for preventing or attenuating the pathophysiologic
changes in remodeling secondary to hypertension.
Blood pressure is considered to be normal when the systolic over diastolic
pressure is 120/80 mm Hg or below. Hypertension is defined as high blood pressure
when the systolic over diastolic pressure is consistently above 140/90 mm Hg (Dugdale,
2011). American Heart Association defines the following categories of hypertension:
Table 1: Categories of Hypertension
Systolic
mm Hg
(upper #)

Blood Pressure
Category
Normal

less than 120

Diastolic
mm Hg
(lower #)
less than 80

Prehypertension

120 – 139

80 – 89

High Blood Pressure
(Hypertension) Stage 1

140 – 159

90 – 99

High Blood Pressure
(Hypertension) Stage 2

160 or higher

100 or higher

Hypertensive Crisis (Emergency
care needed)

Higher than 180

Higher than 110

Source: Understanding Blood Pressure Readings - American Heart Association,
2012

As shown in table 1, blood pressure in the range of systolic over diastolic
pressure of 120-139/80-89 mm Hg is considered as prehypertension and individuals in
this range are advised to do lifestyle modifications such as reduce salt intake or
increase the amount of exercise to prevent redevelopment of hypertension. Multiple
consistent readings of systolic over diastolic pressure of 140/90 mm Hg or higher and
3

160/100 or higher is considered stage I and stage II hypertension, respectively and it
has to be therapeutically treated with anti-hypertensive medications and lifestyle
modifications to maintain it within the normal range (Understanding Blood Pressure
Readings - American Heart Association, 2012). Hypertensive crisis develops when
blood pressure increases to systolic/diastolic of 180/110 or higher and the person has to
be given emergency medical treatment to control it and prevent severe organ damage
(Hypertensive Crisis- American Heart Association, 2012).
Hypertension can be caused secondary to several conditions such as
pheochromocytoma, hyperaldosteronism, renal artery stenosis or it can be idiopathic,
also known as essential hypertension, where the exact cause is unknown. The majority
of the cases of hypertension fall under the idiopathic category and although the exact
cause cannot be pinpointed, stress levels, dietary habits and lifestyle are known to be
major contributing factors (High Blood Pressure or Hypertension - American Heart
Association, 2012)
Chronic hypertension is a persistent stimulus, which increases the afterload of the
heart and induces remodeling progressively over a period of time. It can lead to
hypertensive heart disease, which primarily involves left ventricular hypertrophy and
fibrosis. This can further cause systolic or diastolic dysfunction leading to heart failure.
Controlling hypertension with medications such as β- blockers, angiotensin receptor
blockers and ACE (angiotensin converting enzyme) inhibitors can slow down the
progression of ventricular remodeling or even reverse early remodeling changes and
reduce the associated risk of heart failure (Drazner 2011, Lorell and Carabello 2000).
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Hypertension Induced Left Ventricular Remodeling
Remodeling of the left ventricle (LV) induced by hypertension causes increase in
LV mass and mainly consists of myocyte hypertrophy and changes in the ECM which
give rise to fibrosis (Schwartzkopff et al., 1993; Berk et al., 2007; Spinale, 2007). Along
with the mechanical stress of the increased afterload, various hormones, growth factors,
vasoactive peptides, catecholamines and cytokines contribute to the remodeling
process via multiple pathways (Drazner, 2011). These changes will be further described
in detail below.

a. Hypertrophy
Myocyte hypertrophy is essentially an increase in the size of the myocytes
caused by an increase in the number of sarcomeres, which constitute the contractile
machinery of these cells. The transduction of mechanical stress on the heart into a
hypertrophic response is not yet completely understood but it is known to involve a
range of complex signaling pathways, effects of neurohormonal molecules and
activation of fetal genes (Swynghedauw et al., 1999; Lorell and Carabello, 2000).
Neurohormones such as angiotensin II (Ang II) and endothelin-1 (ET-1) signal through
G-protein coupled receptors, mainly those coupled to Gαq, and receptor tyrosine kinases
to activate the downstream calcium dependent hypertrophic signaling pathways. Some
of the known calcium dependent pathways involved in the hypertrophic response are
CamKII/HDAC-pathway, the calcineurin-NFAT-pathway and the extracellular-regulated
kinases 1 and 2 (ERK1/2). (Kehat and Molkentin, 2010).
5

Cardiac hypertrophy can be concentric or eccentric. Concentric hypertrophy
typically occurs secondary to pressure overload wherein the individual myocytes
increase in width with addition of sarcomeres in parallel. This leads to thickening of the
chamber wall with either no change or a decrease in chamber size (figure 1). Eccentric
hypertrophy usually occurs secondary to volume overload (Lorell and Carabello 2000;
Kehat and Molkentin, 2010). Eccentric hypertrophy is a result of lengthening of
individual myocytes with addition of sarcomeres in series, which leads to increase in the
chamber size. Concentric hypertrophy can lead to diastolic failure while eccentric
hypertrophy can lead to systolic failure over a period of time. However, concentric
hypertrophy can also progress to eccentric hypertrophy during transition to the
maladaptive or decompensated stage of remodeling and further lead to heart failure
(Kehat and Molkentin, 2010; Gaasch and Zile, 2011) (figure 1).

Figure 1: Different types of hypertrophy: Physiologic, concentric and
eccentric. Concentric and eccentric can progress to heart failure.
(Kehat and Molkentin, 2010)
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b. Changes in the Extracellular matrix
The myocytes are supported by a scaffolding of the extracellular matrix (ECM),
which gives a structural support to the myocyte and non myocyte cells of the heart,
maintains electrical communication between the myocytes and aids in transmission of
mechanical forces across the myocardium during systole and diastole.

b.1. Cardiac Fibroblasts
Cardiac fibroblasts (CFs) are flat spindle-shaped resident cells of the extracellular
matrix which are smaller but more numerous than myocytes and make up for the
majority of 70% of non-myocyte type of cells in the heart (Porter and Turner, 2009). CFs
are the key cells involved in maintaining the homeostasis of the ECM, the structural
integrity of the heart and regulating changes in the ECM under disease conditions.
CFs are present in a highly organized manner where they are connected to
neighboring fibroblasts as well as myocytes to facilitate transduction of mechanical
forces and electrical and signaling mechanisms. CFs are the cells solely responsible for
the production and secretion of collagen type 1 and 3, which make up most of the ECM
content (Brown et al., 2005; Baudino et al., 2006).
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b.2. Collagen Synthesis and Degradation

Figure 2: Collagen synthesis and metabolism. Collagen is synthesized as procollagen which
undergoes maturation into collagen fibers and bundles. Collagen is degraded by MMPs.
(Brown et al., 2005)

Fibrillar collagen is first synthesized as procollagen inside the cell and transported
to the endoplasmic reticulum where hydroxylation of proline and lysine residues occurs.
The procollagen is then secreted from the cells in the extracellular space and acted
upon by procollagen peptidases to cleave the amino and carboxy terminal propeptides.
The mature collagen molecules are then assembled and cross-linked to form collagen
8

fibrils, which are further linked to form collagen fibers (Brown et al., 2005). Type 1 and 3
collagen constitute the major fibrillar collagen types with type 1 and 3 accounting for
about 80% and 10% of the ECM, respectively (Medugorac, 1980; Weber et al., 1989;
Speiser et al., 1991; Porter and Turner, 2009). Type 1 collagen provides rigidity to the
ECM and has the tensile strength approaching that of steel (Burton, 1954) while type 3
provides elasticity to ensure compliance of the ventricle during diastolic relaxation and
filling. CFs also produce the proteolytic enzymes, matrixmetalloproteinases (MMPs),
which are a family of over 20 zinc-dependent enzymes involved in degradation of all the
proteins of ECM. Degradation of collagen by MMPs leads to release of stable carboxyterminal telopeptides ([I/III] CTP) (Visse & Nagase, 2003; Raffetto & Khalil, 2008).
Tissue inhibitors of metalloproteinases (TIMP) are proteins secreted by the CFs whose
most important function is to regulate and inhibit the action of MMPs. MMPs and TIMPs
are co-expressed and their functions are well-balanced to regulate the turnover of
collagen and maintain the integrity of the ECM (Porter and Turner, 2009; Moore et al.,
2012).
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b.3 Structure of the Normal Extracellular Matrix and Changes in Hypertension
induced Remodeling
The ECM consists of an extensive elastic network of fibrillar collagen, of which
collagen type 1 and 3 are the main abundant forms but also small amounts of collagen
types 4, 5 and 6. However, the ECM also consists of elastin and fibrillin, fibronectin,
laminin, proteoglycans and glycoproteins.

Figure 3: Structure of the ECM in normal heart and hypertensive heart disease (HHD).
(Berk et al, 2007)

The endomysium in the ECM is composed of collagen fibers surrounding
individual myocytes and those joining adjacent myocytes. The perimysium consists of
collagen bundling together groups of myocytes while the epimysium surrounds bundles
of perimysium (Berk et al., 2007).
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In hypertension induced ECM remodeling, studies have shown perimysial and
endomysial fibrosis as well as perivascular fibrosis around the coronary arterial vessels.
(Berk et al., 2007). This is caused by a disruption in the equilibrium of the activities of
pro and anti-fibrotic mediators involved in a hypertensive state leading to an increased
synthesis and deposition of collagen and decreased degradation. The resulting excess
in collagen (fibrosis) affects the electrical communication between the myocytes and
disrupts their excitation contraction coupling during systole and diastole. It also leads to
decreased LV distensibility or compliance, impaired LV filling and diastolic or systolic
heart failure.
An abnormal increase in collagen content in postmortem human hearts and
myocardial biopsies from hypertensive patients with left ventricular hypertrophy has
been demonstrated by several studies (Tanaka et al., 1986; McLenachan and Dargie,
1990; Ciulla et al., 1997; Rossi, 1998; Brilla et al., 2000). A study by Pardo-Mindán and
Panizo (1993) found collagen type 1 and 3 to be excessively deposited in the
myocardial interstitium and around coronary vasculature in patients having essential
hypertension. Increased synthesis of collagen type 1 in patients having hypertension
induced heart failure was demonstrated in a study by Querejeta et al. (2004). Mukherjee
and Sen (1990) studied alterations in collagen phenotype in spontaneously
hypertensive rats (SHR) (an animal model of hypertension and remodeling). The
authors concluded that there is an increase in deposition of collagen type 1 during the
initial stages of hypertrophy while increased collagen type 3 deposition found at the later
stages is associated with a transformation from the compensated to the decompensated
state of myocardial dysfunction.
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b.4. Functions of CFs in Remodeling
CFs are subjected to cyclic mechanical stretch with every cardiac cycle. But
under pathological conditions such as chronic hypertension, the intensity and frequency
of the stretch increases leading to changes in the function and phenotype of CFs and
resultant composition of the ECM (MacKenna et al., 2000; Gupta and Grande-Allen,
2006). Fibroblasts undergo a phenotypic change to myofibroblasts (having myocyte like
properties). Myofibroblasts express alpha smooth muscle actin (α-SMA) and are
capable of contractile and migratory functions (Leslie KO et al., 1991; Berk et al., 2007).
They have a higher proliferation rate, can migrate to sites of injury such as those
caused by ischemia and infarction and cause greater production of collagen and rapid
remodeling of the ECM (Arora PD and McCulloch CA, 1994; Campbell SE et al., 1995;
Petrov VV et al., 2002). Baicu et al. (2012) found that CFs increased the expression of
total collagen 2 weeks after pulmonary artery banding in a feline model of pressure
overload and increased production of collagen when the pressure overload became
chronic at 4 weeks. Stewart et al. (2010) demonstrated that CFs increased their
proliferation and migration after 7 days of abdominal aortic constriction induced
pressure overload and this response was concomitant with the onset of hypertrophy and
fibrosis within a similar time frame in this rat model of pressure overload.
Increase in mechanical load on the heart induces a profibrotic effect and leads to
enhanced gene expression of growth factors and cytokines such as transforming growth
factor-β (TGF-β), tumor necrosis factor-α (TNF-α), angiotensin II (Ang II) and
endothelin-1 (ET-1) (Weber et al., 1994; Segura et al. 2012). The CFs are stimulated by
autocrine and paracrine secretion of these pro-fibrotic factors to produce and deposit
12

excess collagen in the ECM. The excess collagen deposition leads to fibrosis, which
makes the walls of the ventricles thicker and stiffer ultimately affecting cardiac function.

b.5. Role of Profibrotic Factors
Chemokines are involved in immune cell trafficking and help to recruit monocytes,
leukocytes and neutrophils to the site of action in response to an injury or inflammatory
stimulus (Dobaczewski and Frangogiannis, 2010). MCP-1 (monocyte chemoattractant
protein-1), also known as CCL2, belongs to the CC chemokine family and is mainly
involved in recruiting monocytes, memory T lymphocytes and natural killer cells (NK)
(Valente et al., 1988; Matsushima et al., 1989; Deshmane et al., 2009). MCP-1 is known
to be transiently expressed in the endothelium and media of the coronary vasculature in
response to hypertension induced by suprarenal abdominal aortic constriction in a
pressure overload animal model as seen in a study by Kai et al. (2005). MCP-1 causes
chemotaxis of monocytes by extravasation from the circulation. Monocytes are
differentiated into macrophages at the tissue specific sites. Macrophages are a source
of different cytokines and pro-fibrotic factors such as TNF-α, TGF-β and PDGF (platelet
derived growth factor), which stimulate conversion of fibroblasts to myofibroblasts and
promote their fibrotic response (Murray and Wynn, 2011). Thus, MCP-1 is known to play
an important role in the inflammatory response associated with myocardial infarction
(Dobaczewski and Frangogiannis, 2010).
Animal models of pressure overload induced hypertension are known to involve
an initial inflammatory phase, which subsides later on (Baumgarten et al., 2002;
13

Higashiyama et al., 2006). A study by Kuwahara et al. (2004) showed an increase in
MCP-1 mRNA expression at 3 days post induction of pressure overload in rats by
suprarenal abdominal aortic constriction and the expression was found to subsequently
decline. Treatment with an anti-MCP-1 neutralizing antibody was found to reduce
macrophage accumulation seen in the transient inflammatory phase, TGF- β induction
and myocardial fibrosis but had no effect on cardiac hypertrophy (Kuwahara et al.,
2004).
Cardiac fibroblasts have been shown to express MCP-1 (Behr et al., 2000;
Manabe et al., 2002). A study by Kermani et al. (1996) demonstrated that MCP-1 can
directly stimulate increased secretion of TGF-β1 by lung fibroblasts, which then further
stimulates them in an autocrine loop to increase collagen synthesis. MCP-1 could also
possibly increase expression of the profibrotic factor TGF- β by CFs, which can further
stimulate them in an autocrine manner to increase collagen production.

The renin angiotensin system is known to be activated in response to
hypertension and other pathological stimuli (Timmermans and Smith, 1994; Weber et
al., 1994) and Ang II is an important player in the fibrotic process. Ang II has been
shown to promote fibrosis via AT1 receptors by directly stimulating proliferation of CFs
and production of collagen and other ECM components (Sadoshima and Izumo, 1993;
Kawano et al., 2000; Bouzegrhane and Thibault, 2002). Ang II is also known to activate
fibroblast activities indirectly by autocrine/paracrine stimulation by increased expression
of TGF-β1 (Dostal, 2001; Schultz et al., 2002).
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Transforming growth factor-beta (TGF-β) is an important profibrotic factor in
cardiac remodeling. TGF-β expression is up regulated in conditions such as ischemia,
infarction or mechanical overload (Manabe et al., 2002). It has been shown to stimulate
conversion of fibroblasts to myofibroblasts by inducing expression of α-SMA (Eghbali et
al., 1991; Desmoulière et al., 1993). TGF-β is known to directly stimulate the
proliferation and migration of CFs as well as increase their collagen synthesis and
decrease collagen breakdown in cardiovascular disease states (Villarreal and Dillmann,
1992; Kuwahara et al., 2002; Manabe et al., 2002).

Tumor necrosis factor- α (TNF- α) is another known profibrotic factor playing a
role in cardiac remodeling. It is induced in response to hypertension, MI or other
pathological stimuli and patients with chronic heart failure have been documented to
have increased TNF-α levels in their circulation (Segura et al., 2012). A study by
Yokoyama et al. (1999) showed that TNF- α production by neonatal cardiac fibroblasts
can be stimulated by Ang II as well as mechanical stretch. Transgenic mice having
cardiac restricted overexpression of TNF-α go on to develop dilated heart failure with
myocyte apoptosis and overt fibrosis (Bryant et al., 1998).
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Introduction to Endocannabinoid system (ECS)
The endocannabinoid system (ECS) has been classically thought of as a
neuromodulatory system in the brain constituting the cannabinoid receptors (CB1 and
CB2), their endogenous ligands [anandamide and 2-arachidonoyl glycerol (2-AG)] and
the enzymes involved in their synthesis and degradation (Gole, 2010, pg.9). The
endocannabinoid system is currently under extensive research for the multiple roles it
plays in various physiological systems. Its biological effects on the brain have been
highly researched due to the widespread use of marijuana obtained from the plant
Cannabis sativa. Δ9-tetrahydrocannabinol (THC) has been found to be the predominant
psychoactive constituent of marijuana (Mechoulam and Gaoni, 1967). In the 1980s and
early 1990s, studies done with THC led to the discovery of the CB1 receptors in the
brain and the CB2 receptors mainly in the periphery. Devane and group first discovered
the cannabinoid CB1 receptor in 1988 and it was cloned in 1990 (Matsuda et al, 1990)
while the cannabinoid CB2 receptor was cloned in 1993 (Munro et al.).
CB1 receptors have been known to be highly expressed in the brain and to a
lesser extent in the peripheral organs, comparatively (Pertwee, 1997; Howlett et al.,
2002). The CB2 receptors had been first found to be mainly expressed on different cells
of the immune system but have been recently found in the brain, gut, liver, heart and
other peripheral organs as well (Onaivi et al., 2006; Pacher and Mechoulam, 2011).
Several lines of evidence obtained over the recent years have also suggested the
existence of novel cannabinoid receptors (Begg 2005). The GPR55 receptor has been
known to be a G-protein coupled novel cannabinoid receptor (Sawzdargo et al., 1999).
It has been found to be receptive to the cannabinoid agonist, CP55940, anandamide
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and cannabidiol while lysophosphatidylinositol (LPI) and its 2-arachidonoyl glycerol
derivative have been considered to be its natural ligands (Ryberg et al., 2007; Okuno
and Yokomizo, 2011). Studies have also shown that the peroxisome-proliferatoractivating receptors (PPARs) α and γ could be activated by the endocannabinoids at
high concentrations (O'Sullivan, 2007) while the transient receptor potential vanilloid
subtype 1 (TRPV1) could be activated by anandamide (Starowicz et al., 2007).
Research has shown the existence of novel cannabinoid receptors including the
putative CB2-like cannabinoid receptor, non-CB1 endothelial receptor coupled to Gi/o
and protein kinase G (Mukhopadhyay et al., 2002; Begg et al., 2003) and a putative
receptor for anandamide and R-(+)-WIN55212 found in several regions of the brain
(Howlett et al., 2002).
The cannabinoid receptors are G-protein coupled receptors, mainly linked to the
Gi/o-signaling pathways but they have also been found to couple to several pathways
including Gs and Gq proteins, mitogen activated protein kinases (MAPK) and protein
kinase B (Howlett, 2005). Anandamide has been known to act as a partial agonist and
2-AG as a full agonist at both the CB1 and CB2 receptors (Hillard, 2000). The
endocannabinoids are not stored in vesicles like the classical neurotransmitters. They
are produced on demand and at the site of action and act as retrograde messengers in
the brain. N-arachidonylphosphatidyl ethanolamine (NAPE) has been identified as the
phospholipid precursor for the synthesis of anandamide (Liu et al., 2008) by the calcium
dependent enzyme NAPE specific phospholipase D (Okamoto et al., 2004) while
anandamide has been found to be degraded by the enzyme, fatty acid amide hydrolase
(FAAH). Phosphatidylinositol derived diacylglycerol (DAG) has been shown to be the
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precursor for the synthesis of 2-AG carried out by the enzymes DAG lipases α and β
(Bisogno et al., 1997) while metabolism of 2-AG is known to be carried out by the
enzyme monoacylglycerol lipase (MAGL). Studies have shown that the
endocannabinoids can also be metabolized by cyclooxygenases, lipoxygenases, and
cytochromes P45 (Rouzer and Marnett, 2011). The existence of membrane
transporters, which carry out cellular reuptake of both the endocannabinoids, has been
postulated as a result of the existence of compounds thought to be cellular uptake
inhibitors such as AM404 and OMDM-2 (Beltramo et al., 1997; Hermann et al., 2006;
Chicca et al., 2012). The endocannabinoids and CB1 agonists have been known to
modulate the release of neurotransmitters such as noradrenaline, dopamine, serotonin
and acetylcholine in different brain areas implicated in mood, memory and motor
disorders (Szabo and Schlicker, 2005). Owing to the ubiquitous expression of the ECS
in different organ systems of the body, it has been implicated in a variety of disorders
such as obesity, liver fibrosis/ cirrhosis, cancer, multiple sclerosis, pain, nephropathy as
well as a number of cardiovascular disorders (Pacher et al., 2006). Recently, the Food
and Drug Administration has approved the use of THC (known as dronabinol, trade
name- Marinol; Solvay Pharmaceuticals, Brussels, Belgium) for the treatment of
chemotherapy associated nausea and vomiting and for loss of appetite and weight loss
associated with acquired immunodeficiency syndrome (AIDS) (Dronabinol: Medline Plus
Drug Information- National Library of Medicine, 2010) and its synthetic analogue
nabilone (Cesamet; Valeant Pharmaceuticals, Irvine, CA, USA) for treatment of nausea
and vomiting caused by chemotherapy (Nabilone: Medline Plus Drug Information National Library of Medicine, 2010)
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ECS in Cardiovascular Physiology and Disease States
The endocannabinoid system was thought to be initially involved in
cardiovascular functions with the observation in humans as well as experimental
animals of an increase in heart rate following acute use of THC and a decrease in heart
rate and blood pressure on chronic use (Rosenkratz, 1974; Benowitz and Jones, 1975).
These observed effects of THC were found to be mediated by the cannabinoid
receptors (CB1 and CB2), which have only recently been identified in the heart and
vasculature in the past decade (Liu et al, 2000; Bonz et al., 2003; Shmist et al., 2006;
Mukhopadhyay et al., 2007). Subsequent studies done with exogenously administered
endocannabinoids (anandamide and 2-AG) found that both agents: 1) reduce blood
pressure via a direct vasodilatory effect; 2) decrease cardiac contractility; and 3) cause
bradycardia via inhibition of norepinephrine release by presynaptic CB1 receptors (for
review, see Pacher et al., 2005). These effects on blood pressure were found to be
tissue and species specific and mediated via various receptors including CB1, vanilloid
(TRPV1) and novel non-CB1, CB2 receptors (putative endothelial cannabinoid receptor)
(Pacher et al., 2005). Ensuing studies focused on specific cannabinoid receptor type
and the role played by this system in various cardiovascular disorders and found that
the endocannabinoid system is activated under cardiovascular pathological states.
CB1 receptor antagonism has been shown to be protective against myocardial
infarction by reduction in infarct size after treatment with rimonabant, a synthetic CB1
antagonist (Lim et al., 2009). CB1 antagonists exerted protective effects on
cardiomyocytes, both in vivo and in vitro, against doxorubicin induced cardiotoxicity
(Mukhopadhyay et al., 2007). Further, reduced levels of collagen and profibrotic factors
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in CB1 null mice were reported in the model of doxorubicin induced oxidative stress and
fibrosis (Mukhopadhyay et al., 2010). A study by Rajesh et al. (2008) showed inhibitory
effect of rimonabant on proliferation and migration of human coronary artery smooth
muscle cells, which may have a beneficial effect in atherosclerosis and restenosis.
Further, CB1 antagonism with rimonabant was found to inhibit macrophage recruitment
and atherosclerotic development in mice (Dol-Gleizes et al., 2009). A recent study by
Slavic et al. (2013) demonstrated protective effects of rimonabant against fibrosis and
cardiac remodeling after myocardial infarction (MI). CB1 antagonism reduced collagen
content, downregulated TGF-β1 expression and improved systolic and diastolic cardiac
function after MI in a rat model. There are also some discrepancies in the literature with
a few studies showing deleterious effects of CB1 receptor antagonism (Wagner et al.,
2003; Mendizabal and Graschinsky, 2007). Also, CB1 activation was shown to have a
cardioprotective effect in a mouse model of acute heart failure via inhibition of excessive
sympathetic tone (Liao et al., 2012). Reasons for the disparate findings could be due to
the complexity of the system with the receptors being linked to numerous signaling
pathways, its tonic activation and inactivation under pathological conditions, species
and experimental differences. However, to date effects of CB1 activation or receptor
blockade in the setting of hypertension induced remodeling remains to be elucidated.
CB2 receptor activation demonstrated cardioprotective effects in a rat model of
ischemia/reperfusion (I/R) leading to reduction of infarct size via p38, ERK ½ and PKC
(protein kinase C) activation (Lepicier et al. 2003). WIN-55212-2 (non-specific CB1 and
CB2 agonist) showed a reduction in reperfusion injury and infarct size as well as
decreased activation of macrophages and local generation of cytokines (Di Fillipo et al.,
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2004) Further, this beneficial effect was blocked by a specific CB2 antagonist, AM630,
thus indicating involvement of CB2 receptors in mediating a cardioprotective effect by
reducing recruitment of inflammatory cells in I/R injury (Di Fillipo et al., 2004).
Treatment with JWH-133, a specific CB2 agonist, was able to reduce infarct size in a
mouse model of I/R when administered shortly before reperfusion and this effect was
abolished by the CB2 antagonist, AM630. The cardioprotective effect of CB2 receptors
was mediated by three mechanisms, a reduction in superoxide production, which is an
early mediator of I/R injury, reduction in neutrophil recruitment and activation of ERK 1/2
and STAT-3 (c) phosphorylation, which is a protective mechanism against myocardial
damage after I/R (Montecucco et al., 2009). A study by Defer et al. (2009) demonstrated
that CB2 null mice show pervasive myocardial injury, increased myofibroblast
differentiation and extensive fibrosis after I/R and the authors concluded that CB2
receptors may play a role in promoting myocyte and fibroblast survival and reduce
fibrosis associated with I/R. The synthetic cannabinoid agonist, HU-210 acting via CB2
receptors was found to reduce incidence of ventricular arrhythmias after coronary
occlusion and reperfusion (Krylatov et al. 2001). CB2 receptor activation has also been
shown to exert an anti-inflammatory effect and attenuate TNF- α induced human
coronary endothelial cell activation, expression of MCP-1, transendothelial migration of
monocytes and their adhesion to endothelium (Rajesh et al., 2007). It is also known to
reduce proliferation and migration of human vascular smooth muscle cells induced by
TNF- α (Rajesh et al., 2008). Overall, most of the evidence has demonstrated that CB1
antagonism and CB2 agonism is beneficial in cardiovascular disorders such as
myocardial infarction and ischemia, cardiomyopathy and atherosclerosis.
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The role played by the ECS in cardiac remodeling secondary to pressure
overload has not yet been extensively investigated. The current knowledge base lacks
in establishing the effects of pathophysiologic remodeling changes secondary to
pressure overload induced hypertension on myocardial expression of cannabinoid CB1
and CB2 receptors and their temporal response to the progressive remodeling changes.
We hypothesize that myocardial cannabinoid CB1 and CB2 expression is altered in
response to pressure overload induced cardiac remodeling.
The function of CB1 and CB2 cannabinoid receptors in cardiac ventricular
fibroblasts and their downstream fibrotic pathways has not yet been studied.
Mukhopadhyay et al. (2010) undertook an in vivo study to show CB1 receptors can
promote fibrosis in doxorubicin induced cardiomyopathy. Work by Defer et al. (2009)
and other groups demonstrated that CB2 receptors can prevent fibrosis in the ischemic
heart as well as other tissues such as liver and pancreas (Munoz-Luque et al., 2008;
Michalski et al., 2008). Investigating the direct effects of modulation of cannabinoid
receptors on cardiac fibroblasts could elucidate a potential anti-fibrotic effect mediated
by the endocannabinoid system and thus a novel therapeutic approach. We
hypothesize that antagonism of the CB1 receptors expressed on cardiac ventricular
fibroblasts would have an antifibrotic effect while antagonism of the CB2 receptors
would have a profibrotic effect.
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OBJECTIVES

The primary objectives of the present study are:
Aim 1: To determine alterations in cannabinoid CB1 and CB2 receptors in a rat
model of cardiac remodeling secondary to pressure overload.
Aim 1.1: To determine levels of collagen and pro-inflammatory factor, MCP-1 (monocyte
chemoattractant protein-1) in left ventricular extracts secondary to pressure overload.
Aim 1.2: To demonstrate expression of CB1 and CB2 receptors on fibroblasts in rat left
ventricular tissue.
Aim 1.3: To determine the temporal expression pattern of CB1 receptors in the left
ventricle at 3, 5, 14 and 28 days post induction of pressure overload.
Aim 1.4: To determine the temporal expression pattern of CB2 receptors in the left
ventricle 3, 5, 14 and 28 days post induction of pressure overload.
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Aim 2: To determine the effects of CB1 cannabinoid receptor modulation on
human ventricular fibroblasts (HVF).
Aim 2.1: To determine expression of CB1 receptors on HVF.
Aim 2.2: To measure changes in total collagen and expression of collagen type 1 and
type 3 after treatment of CB1 antagonist, AM251.
Aim 2.3: To determine levels of MCP-1 after treatment of CB1 antagonist, AM251.

Aim 3: To determine the effects of CB2 cannabinoid receptor modulation on
human ventricular fibroblasts (HVF).
Aim 3.1: To determine expression of CB2 receptors on HVF
Aim 3.2: To measure changes in total collagen and expression of collagen type 1 and
type 3 after treatment of CB2 antagonist, AM630.
Aim 3.3: To determine levels of MCP-1 after treatment of CB2 antagonist, AM630.
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MATERIALS AND METHODS

Drugs: 3 compounds, 2- Arachidonoyl glycerol, AM251 and AM630, were used in the in
vitro study. Appropriate vehicle controls were used for all the three compounds.

2-Arachidonoyl glycerol (2-AG): 2-AG was obtained from Tocris Bioscience
(Minneapolis, MN). It is an endogenous cannabinoid agonist at both CB1 (Ki = 472 nM)
and CB2 (Ki = 1400 nM) receptors. The 10 uM solution of 2-AG was made in ethanol.

AM251: AM251 [(1- (2, 4- Dichlorophenyl)- 5- (4- iodophenyl)- 4- methyl- N- 1piperidinyl- 1H- pyrazole- 3- carboxamide] was purchased from Cayman chemicals (Ann
Arbor, MI). It is a potent CB1 receptor antagonist (IC50 = 8 nM, Ki = 7.49 nM) that
displays 306-fold selectivity over CB2 receptors. The 10 uM solution of AM251 was
made in ethanol and the final concentration of ethanol in the culture media during cell
treatments was 1%.

AM630: AM630 {[6- Iodo- 2- methyl- 1- [2- (4- morpholinyl)ethyl]- 1H- indol- 3- yl](4methoxyphenyl)- methanone} was obtained from Cayman chemicals (Ann Arbor, MI). It
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is a CB2 antagonist/inverse agonist (Ki = 31.2 nM) that displays 165-fold selectivity over
CB1 receptors. It also behaves as a weak partial/inverse agonist at CB1 receptors with
a Ki = 5.2 µM. The 10 uM solution of AM630 used in the study was made in DMSO and
the final concentration of DMSO in the culture media during cell treatments was 0.1%.

Animals
9 week old Sprague Dawley rats were used for the study. Rats were housed in a
standard temperature and humidity controlled colony room with a 12 h light/12 h dark
cycle. Food and water were provided ad libitum. All rats were randomly selected for
each group. All the procedures involving animals were approved by the Institutional
Animal Care and Use Committee of the University of Mississippi according to the
National Institutes of Health Guide for Care and Use of Laboratory Animals.

Abdominal Aortic Constriction Model of Pressure Overload
Pressure overload was induced in rats by abdominal aortic constriction as
described in Nagalla et al. (2012). Anesthesia was induced and maintained by using 2%
Isoflorane in adult male rats. A sterile heated pad was placed under the animals to
maintain their core body temperature. The abdominal skin was sterilized and a midline
incision was made under the xiphoid process using surgical scissors. The linea alba
was exposed and an incision was made to create a ventral laparotomy. The left
abdominal wall of the animal was retracted and maintained in that position using
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magnetic clips. The intestines were retracted to one side and the right and left renal
arteries arising from the abdominal aorta were identified. A small 21-gauge needle was
placed on the part of the abdominal aorta between these two arteries and a size-0 silk
suture was tied around the needle and the aorta to partially constrict the aorta to the
external diameter of the needle. The needle was quickly removed and the intestines
were positioned back in the abdominal cavity. The cut abdominal musculature was
closed with an absorbable suture (Chromic 3-0) followed by closure of the skin with skin
staples. Sham animals were subjected to the same surgical procedure but without
constriction of the abdominal aorta. The animals were then placed in ambient heated
units to recover from the anesthesia and surgery.

Assessment of Cardiac Function
Cardiac function was assessed at 14 and 28 days after the induction of
pressure overload by abdominal aortic constriction using a ScisenseTM admittance
catheter (FTS-1912B; Scisense Inc, London Ontario, Canada) as previously
described (Pacher et al., 2008; Nagalla et al., 2012). Rats were anesthetized using
isofluorane gas contained in an anesthesia chamber. Then the anesthesia was
maintained throughout the procedure using sodium pentobarbital at a dose of 10%
body weight administered i.p. Animals were placed on a heated pad to maintain their
body temperature. An incision was made in the mid neck area and the right carotid
artery was exposed after blunt dissection of the thin muscle layer around the throat.
The pressure volume conductance catheter was carefully advanced into the left
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ventricle (LV) via an incision made in the right carotid artery to measure the LV
chamber volume and function. Data were analyzed using iWorx© (Dover, NH)
Labscribe Instrument software. Mean Arterial Pressure was calculated as Diastolic
pressure + 1/3 (Systolic pressure – Diastolic Pressure).

Tissue isolation
The hearts were extracted from anesthetized rats at the end of measurement of
cardiac parameters. The right and left ventricles were identified, separated and
weighed. A thin cross-section was cut from the base of the left ventricle and fixed in 4%
paraformaldehyde for use in immunohistochemistry. Another section was cut and flash
frozen and the non-septal region was used for total collagen measurement by analysis
of hydroxyproline content. The remaining portion of the LV containing the apical region
was cut into smaller pieces and flash frozen in liquid nitrogen for further biochemical
analyses.

Tissue homogenization and protein extraction
The left ventricles from the rats were homogenized and centrifuged and the
supernatant was used for biochemical analyses. 100 mg of tissue was weighed from
each rat and 800 ul of homogenizing buffer (PBS + 1X PIC) was added to each sample
in a glass test-tube. The tissue was homogenized using a hand held homogenizer. 80 ul
of cell membrane disruption buffer (10% PBS+Triton X-100) was added to each tube
and the samples were vortexed and kept on ice for 30 minutes with intermittent mixing
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after every 10-15 minutes. The homogenate was then centrifuged for 30 minutes at
16000 RPM at 4 oC. The supernatant was collected for protein quantification and other
assays.

Protein quantification
Total protein quantification of each sample was done using the DCTM protein
assay (BIO-RAD, Hercules CA). Bovine serum albumin was used to make five protein
standards (0.1, 0.25, 0.5, 1.0, 1.5 and 2 mg/ml) in 0.1% PBS+Triton X-100 (PBST). The
left ventricle tissue samples were diluted 10 times using PBST. 5 ul of standards and
samples were added to each well of a 96-well plate in triplicates. Next, 25 ul of activated
Reagent A was added to each well followed by 200 ul of Reagent B as per the
manufacturer’s instructions. The plate was incubated for 15-30 minutes at room
temperature (RT) and the absorbance was read at 750 nm on the microplate reader
(BioTek, Winooski, VA). The sample dilution was adjusted for in the final calculations of
protein concentration (ug/ul) of each sample.

Immunohistochemistry
Immunohistochemistry was performed on rat left ventricular cross-sections fixed
in 4% paraformaldehyde to demonstrate expression of CB1 and CB2 receptors on
cardiac fibroblasts. LV cross-sections from each sample were paraffin embedded, cut
into thin cross-sections and fixed on glass slides (HSRL, Inc. Mount Jackson, VA). The
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slides were first deparaffinzed using Xylene (2 X 5 min) and rehydrated in a series of
alcohol concentrations in decreasing order (100%, 95%, 70%, 50%) (30-40 sec each).
They were thoroughly washed in running water followed by antigen retrieval using citric
acid buffer for 20 minutes in a water bath heated to 95-100 oC. The slides were cooled,
washed 2X in water followed by a wash in PBS for 5 minutes each. The sections were
then blocked with 5% donkey serum in 1% BSA in PBS for 1 hour at RT. The blocking
buffer was decanted after 1 hour and the sections were incubated with either rabbit
polyclonal anti-CB1 primary antibody (1:300) in 1% BSA in PBS or rabbit polyclonal
anti-CB2 primary antibody (1:300) in 1% BSA in PBS at 4 oC overnight in the
refrigerator. Next day, the primary antibody solutions were decanted and the slides were
washed in PBS (3 X 5 min) to remove excess primary antibodies. The sections were
then incubated with donkey anti-rabbit secondary antibody labeled with Alexafluor 488
for 1 hour at RT. Post incubation of secondary antibody, the slides were washed with
PBS (3 X 5 min). The sections were then gently dried and mounted with media
containing the nuclear counterstain, DAPI (4',6-Diamidino-2-Phenylindole). The slides
were dried overnight and the images of the LV sections were taken using a laser
scanning confocal microscope.

Western blotting
Western blotting was carried out to determine expression of CB1 and CB2
receptors using LV extracts and human ventricular fibroblast (HVF) cell extracts. Gel
electrophoresis was carried out using 12% Tris-glycine gels. Each lane was loaded with
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equal amounts of protein (ug) from LV extracts or cell lysates. The gels were transferred
onto a nitrocellulose membrane using a semi-dry transfer apparatus. (Biorad, Hercules,
CA). Membranes were blocked with 3% milk in PBS for 3-4 hours at RT and probed with
rabbit anti-CB1 polyclonal antibody (1:200, 3% milk in PBS) (Abcam, Cambridge, MA)
or rabbit anti-CB2 polyclonal antibody (1:200, 3% milk in PBS) (Cayman Chemicals,
Ann Arbor, MI) and rabbit anti-GAPDH polyclonal antibody (Abcam, Cambridge, MA)
overnight at 4 oC. The membranes were washed the next day with 3% milk in PBS (3 X
10 min) and probed with Horse Radish Peroxide tagged goat anti-rabbit polyclonal
secondary antibody for 1-2 hours at RT. Following washes with 3% milk in PBS (3 X 10
min), membranes with developed with ECL chemiluminescent reagent (Thermo
Scientific, Rockford, IL) and visualized with VersadocTM imaging apparatus (Bio-radTM).
The expression of CB1 and CB2 receptor proteins was normalized to GAPDH. The
positive control used was mouse hippocampus, which is known to have an abundance
of CB1 receptors and also known to express CB2 receptors (Pacher et al., 2006).

ELISA (Enzyme Linked Immunosorbent Assay)
Commercially available ELISA kit was used for the analysis of MCP-1 (SA
Biosciences, Valencia, CA) in LV extracts and cell culture media. Briefly, standards and
diluted samples were added to the 96-well plate and incubated for 2 hours at RT. The
plate was washed several times and incubated with the MCP-1 detection antibody
solution for 1 hour at RT. Following the washing step, Avidin-HRP was added to the
plate and incubated for 30 min at RT. The plate was then incubated with the
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development solution for 15 minutes followed by addition of the stop solution. The plate
was read at 450nm on the microplate reader (BioTek, Winooski, VA).

Hydroxyproline Assessment of Total Collagen Concentration
A portion of left ventricular tissue (50 mg) was dried at 60 oC in an oven for 20-24
hours. For the in vitro study, 1 ml of cell culture media from all the samples was dried at
60 oC for 20-24 hours. Dried samples were then hydrolyzed in 6 N hydrochloric acid at
110 oC for 20-24 hours. After hydrolysis, samples were decolorized with activated
charcoal and filtered to remove the charcoal. The filtrate was then lyophilized by
vacuum rotary evaporator. The residue was dissolved in citrate buffer and
hydroxyproline concentration was determined using the method described by Woessner
(1961).

Cell culture
Human ventricular fibroblasts (HVF) (ScienCellTM, Carlsbad, CA) were grown in
DMEM (Cellgro, Manassas, VA) with 10% fetal bovine serum (FBS), 5% neonatal calf
serum (NCS) (Atlanta Biologicals, Flowery Branch, GA), 1X fibroblast growth serum
(FGS) (SciencellTM, Carlsbad, CA), 5ug/ml PlasmocinTM Prophylactic (Invivogen, San
Diego, CA) and 1X Antibiotic – Antimycotic solution (Santa Cruz Biotechnology Inc.,
Dallas, TX). For all the studies except those for qPCR (Real Time Polymerase Chain
Reaction), cells were grown in 100mm cell culture dishes. Cells were grown to
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confluence and serum starved for 24 hours prior to treatment. The treatments with the
cannabinoid compounds were carried out for 48 hours with re-dosing of the drug/s after
24 hours. Media was collected for determination of secreted collagen and MCP-1. Cells
were scraped after addition of cell lysis buffer (Cell Signaling Technology, Danvers,
MA), sonicated and centrifuged at 16000 RPM for 30 min at 4 oC. The supernatant of
the cell extracts was used for further analyses. For qPCR studies, cells were grown in
60 mm culture dishes, serum starved for 24 hours and treated with the cannabinoid
compounds for 24 hours. The media was discarded, cells were washed with PBS and
the RNA was isolated using the RNeasy Mini kit (Qiagen, Valencia, CA).

Immunofluorescence (IF): Human ventricular fibroblasts (HVF)
HVF were cultured and grown on 8 chamber slides. Cells were fixed with 4%
paraformaldehyde, washed with PBS and blocked with 1% BSA in PBS for 1 hour.
Rabbit anti-CB1 and rabbit anti-CB2 antibodies (both at a concentration of 1:100 in 1%
BSA in PBS) (Thermo Scientific, Rockford, IL) were added to the chambers for 1 hour at
RT. Cells were washed with PBS (2 X 10 min) and incubated with goat anti-rabbit
secondary antibody labeled with Alexafluor 488 (1:500 in 1% BSA in PBS) for 1 hour at
RT. Following the incubation with secondary antibody, cells were washed 3X with PBS,
nuclei were counterstained with DAPI and slides were mounted with anti-fade medium
(Invitrogen, Grand Island, NY). The cells were visualized with a Nikon Eclipse 90i
fluorescence microscope.
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Real Time Polymerase Chain Reaction (qPCR)
qPCR was carried out to determine mRNA expression of collagen I and III in HVF.
The RNA was isolated from the HVF with the RNeasy Mini kit (Qiagen, Valencia, CA).
About 200 ng of RNA was reverse transcribed into cDNA using the iScript cDNA
synthesis kit (Biorad, Hercules, CA) from each sample followed by qPCR on the Biorad
CFX Connect qPCR Detection System. FAM labeled TaqMan collagen 1A1 (ref no.
Hs00164004_m1) and collagen 3A1 (ref no. Hs00943809_m1) primers and VIC labeled
TaqMan GAPDH primer (ref no. Hs02758991_g1) were purchased from Applied
Biosystems (Grand Island, NY). The changes in mRNA expression were calculated by
the ΔΔCt method and normalized to the appropriate vehicle controls.

Statistical analyses
All the results were statistically evaluated using Graphpad Prism Version 6.0
(GraphPad Software, San Diego CA, USA). The values are represented as mean ±
SEM. All data with comparison of two groups were analyzed by Student’s T-test and
those with three or more groups were analyzed by one way analysis of variance
(ANOVA) followed by Dunnett’s or Bonferroni’s post hoc test as specified to determine
statistical significance at p ≤ 0.05.
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AIM 1

Aim 1: To determine alterations in cannabinoid CB1 and CB2 receptors in a rat
model of cardiac remodeling secondary to pressure overload.
Aim 1.1: To determine levels of collagen and pro-inflammatory factor, MCP-1 (monocyte
chemoattractant protein-1) in left ventricular tissue extracts secondary to pressure
overload.
Aim 1.2: To demonstrate expression of CB1 and CB2 receptors on fibroblasts in rat left
ventricular tissue.
Aim 1.3: To determine the temporal expression pattern of CB1 receptors in the left
ventricle at 3, 5, 14 and 28 days post induction of pressure overload.
Aim 1.4: To determine the temporal expression pattern of CB2 receptors in the left
ventricle 3, 5, 14 and 28 days post induction of pressure overload.

Rationale:
Hypertension is a rampant disorder afflicting 1 in 3 adults in the United States (Go
et al., 2013). It is a leading cause of cardiac remodeling and predisposes the heart to an
increased risk of failure. Research in the past decade has shown the existence of CB1
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and CB2 receptors in the heart (Bonz et al., 2003; Weis et al., 2010). Studies have
implicated the endocannabinoid system in cardiac remodeling associated with ischemia
and cardiomyopathy, with CB1 receptor antagonists and CB2 receptor agonists linked
to beneficial effects (Lepicier et al., 2003; Defer et al., 2009; Lim et al., 2009;
Mukhopadhyay et al., 2010) However, the role of the endocannabinoid system remains
yet to be actively investigated in cardiac remodeling induced by chronic hypertension. It
is not yet known how the pathophysiologic remodeling changes secondary to pressure
overload induced hypertension affect the myocardial expression of cannabinoid CB1
and CB2 receptors and whether they are altered in a temporal manner. We hypothesize
that myocardial cannabinoid CB1 and CB2 expression is altered temporally in response
to pressure overload induced cardiac remodeling.

Experimental approach:
The animal model of pressure overload (PO) induced by abdominal aortic
constriction is a well-established model of hypertension, which induces extensive
remodeling of the myocytes and extracellular matrix (Ruetten et al., 2005; Kamogawaa
et al., 2001). Unlike other cardiac models of ischemia associated with large oxidative
stress, prolonged infiltration of inflammatory cells and loss of myocytes, this model of
pressure overload only leads to immune cell influx in the first 3-5 days (Higashiyama et
al., 2007).
For this study, pressure overload (PO) was induced in 9-week old male Sprague
Dawley rats by abdominal aortic constriction. Sham animals (controls) underwent the
same surgical protocol except with no constriction of the abdominal aorta. 8 groups of
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rats (n=6/group) were used, 1) 3-day sham, 2) 5-day sham, 3) 14-day sham, 4) 28-day
sham 5) 3-day PO, 6) 5-day PO, 7) 14-day PO and 8) 28-day PO, to compare each PO
group to their respective age and time matched controls.
Cardiac functional parameters were assessed at 14 and 28 days post surgery for
the specific groups using a high fidelity pressure volume catheter in anesthetized rats.
Left ventricular tissues were isolated, weighed and snap frozen from all the animals. A
thin cross-section was cut from each left ventricle and formalin fixed. The LV crosssections were then paraffin embedded and cut into thin sections to be used for
immunohistochemistry (IHC). IHC was performed to demonstrate expression of CB1
and CB2 receptors on rat LV fibroblasts. Western blotting was utilized to determine
temporal changes in expression of CB1 and CB2 receptors in the left ventricular tissue
extracts at the 3, 5, 14 and 28 day time points. The levels of MCP-1 in 3 and 5 day time
point animals were determined by ELISA. Total collagen content in left ventricular
tissues was measured by determination of hydroxyproline concentration in 14 and 28day animals.
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RESULTS

Table 2: Analysis of cardiac parameters at 14 and 28 days in rat pressure
overload (PO) model.
Body Wt

LV Wt

LV/ Body Wt

MAP

(Gms)

(Mgs)

Index

(mmHg)

Sham

335 ± 5

752 ± 47

2.2 ± 0.1

115 ± 7

PO

296 ± 8 *

839 ± 27 *

2.9 ± 0.2 *

155 ± 4 *

Sham

362 ± 14

792 ± 47

2.2 ± 0.1

121 ± 5

PO

353 ± 18

971 ± 80 *

2.8 ± 0.1*

158 ± 11 *

14 Day

28 Day

Table 2: Comparison of body weights, LV (left ventricle) weights, LV/body
weight indices and mean arterial pressure (MAP) at 14 and 28 day time
points in sham and PO rats. Values represented as mean ± standard error
where *p < 0.05. (Student’s T-test)
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Table 2 shows a significant decrease in body weight of rats undergoing pressure
overload surgery at 14 days but the weight was normalized by 28 days as compared to
sham values. The left ventricular mass and LV/body weight index (a classic indicator of
left ventricular hypertrophy) were significantly increased at both 14 and 28 day time
points in PO rats as compared to sham values. However, the significance value of
LV/body weight index at the 14 day time point could have been slightly overestimated
due to the decrease in body weight of this group. Relative to sham values, the mean
arterial pressure (MAP) was also significantly increased at both 14 and 28 day time
points in PO rats (Table 2). These cardiac parameters demonstrate cardiac remodeling
changes secondary to pressure overload induced hypertension.
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Figure 4: MCP-1 (pg/ml) levels in myocardial tissue from sham and PO rats at 3
and 5 day time points.

Figure 4: Levels of MCP-1 (pg/ml) at 3 and 5 day time points in sham and PO rat
myocardial tissue. Data are represented as mean ± SEM, n=6 mice per group
where **p ≤ 0.01 as compared to sham control.

The levels of the inflammatory chemokine MCP-1 were determined by ELISA.
MCP-1 levels were found to be significantly elevated in rat left ventricular tissue extracts
at the 3 day time point post induction of pressure overload as compared to sham values
(figure 4). The elevation seen in MCP-1 was back to control level by day 5.
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Figure 5: Total collagen level in rat myocardium in sham and 14 and 28 day PO
rats.

Figure 5: Total collagen measured by hydroxyproline analysis in LV tissue of agematched sham and 14 and 28 day PO animals. Values are represented as mean ± SEM
where *p ≤ 0.05 as compared to the age-matched shams, #p<0.01 as compared to 14
day PO.

Total collagen content in a portion of the left ventricular septal wall was
determined by the hydroxyproline concentration. Total collagen content was significantly
increased in the 14 day PO animals as compared to their age matched shams as well
as the 28 day PO animals as compared to their age matched shams (figure 5). The
collagen content in the PO group at 28 days was significantly higher than that in the 14
day PO group, indicating progressive fibrosis. There was no significant difference
between either age-matched sham groups (figure 5).
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Figure 6: Expression of CB1 receptors on rat cardiac fibroblasts in left ventricular
cross-section.
(A)

Figure 6(A): Expression of CB1 receptors on rat LV fibroblasts and myocytes. CB1
receptors were detected by using rabbit anti-CB1 antibody and Alexafluor 488 labeled
donkey anti-rabbit secondary antibody. Nuclei were counterstained with DAPI. Red
arrows point towards fibroblasts. Yellow arrow points towards myocyte.
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(B)

Figure 6B: Negative control for CB1 receptors where anti-CB1 primary antibody
was omitted and only Alexafluor 488 labeled secondary antibody was used.
Nuclei were counterstained with DAPI.

Expression of CB1 receptors on fibroblasts in rat LV cross-sections was
determined by fluorescence microscopy using a rabbit polyclonal anti-CB1 primary
antibody and Alexafluor 488 labeled donkey anti-rabbit secondary antibody. Figure 6A
shows an apparent expression of CB1 receptors on the fibroblasts and myocytes in the
LV section. The nuclei were counterstained blue using DAPI. The absence of nonspecific binding of the secondary antibody was confirmed by obtaining a negative
control without the use of the anti-CB1 primary antibody and using only the fluorescent
secondary antibody (figure 6B).
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Figure 7: Temporal expression pattern of myocardial CB1 receptors at 3, 5 day
time points in rat pressure overload (PO) model.

*
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Figure 7: Average Western blot signal intensity of myocardial CB1 receptor
protein levels after normalization to GAPDH at 3 and 5 day time points in sham
and PO rats. Data are represented as mean ± SEM, n=6/group where *p ≤ 0.05
as compared to sham controls.

Myocardial CB1 receptor expression was measured by western blotting in the 3
and 5 day PO animals and the values were normalized to GAPDH. The CB1 expression
was increased significantly at the 3 day time point in PO animals as compared to agematched sham animals as shown in figure 7. There was a downward trend in
expression after day 3 and CB1 expression at 5 days in the PO group was unchanged
from age-matched sham values (figure 7).

44

Figure 8: Temporal expression pattern of myocardial CB1 receptors at 14 and 28
day time points in rat pressure overload model.
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Figure 8: Average Western blot signal intensity of myocardial CB1 receptor protein levels
after normalization to GAPDH at 14 and 28 day time points in sham and PO (pressure
overload) rats. Data are represented as mean ± SEM, n=6 rats per group where *p ≤
0.05, **p ≤ 0.01 as compared to sham controls.

Myocardial CB1 receptor expression was measured by western blotting in the 14
and 28 day PO animals. As shown in figure 8, myocardial CB1 receptor levels were
significantly decreased at the 14 day time point in the PO group as compared to agematched sham values. The CB1 expression was also found to be decreased at the 28
day time point in the untreated PO group as compared to sham values (figure 8).
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Figure 9: Expression of CB2 receptors on rat cardiac fibroblasts in left ventricular
cross-section.
(A)

Figure 9(A): Expression of CB2 receptors on rat LV fibroblasts and myocytes. CB2
receptors were detected by using rabbit anti-CB2 antibody and Alexafluor 488 labeled
donkey anti-rabbit secondary antibody. Nuclei were counterstained with DAPI. Red
arrows point towards fibroblasts. Yellow arrow points towards myocyte.
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(B)

Figure 9B: Negative control for CB2 receptors where anti-CB2 primary antibody
was omitted and only Alexafluor 488 labeled secondary antibody was used.
Nuclei were counterstained with DAPI.

Expression of CB2 receptors on fibroblasts in rat LV cross-sections was
determined by fluorescence microscopy using a rabbit polyclonal anti-CB2 primary
antibody and Alexafluor 488 labeled donkey anti-rabbit secondary antibody. Figure 9A
shows an apparent expression of CB2 receptors on the fibroblasts and myocytes in the
LV section. The nuclei were counterstained blue using DAPI. A negative control was
obtained using only the fluorescent secondary antibody and omission of the anti-CB2
primary antibody to ensure the absence of non-specific binding of the secondary
antibody (figure 9B).
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Figure 10: Temporal expression pattern of myocardial CB2 receptors at 3, 5 day
time points in rat pressure overload model.
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Figure 10: Average Western blot signal intensity of myocardial CB2 receptor protein levels
after normalization to GAPDH at 3 and 5 day time points in age-matched sham and PO
(pressure overload) rats. Data are represented as mean ± SEM, n=6 mice per group where
*p ≤ 0.05, **p ≤ 0.01 as compared to sham control.

Myocardial CB2 receptor expression was measured by western blotting in the 3
and 5 day PO animals and the values were normalized to GAPDH. CB2 receptor
expression was significantly increased at both, the 3 and 5 day time points in the
untreated PO groups as compared to age-matched sham values (figure 10).
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Figure 11: Temporal expression pattern of myocardial CB2 receptors at 14 and 28
day time points in rat pressure overload model

*

Myocardial CB2 protein levels
(normalized to GAPDH)

0.40
0.35
0.30
0.25
0.20
0.15
0.10
0.05
0.00

Sham

PO-14

PO-28

Groups

Figure 11: Average Western blot signal intensity of myocardial CB2 receptor protein
levels after normalization to GAPDH at 14 and 28 day time points in age-matched
sham and PO rats. Data are represented as mean ± SEM, n=6 mice per group
where *p ≤ 0.05 as compared to sham control.

Myocardial CB2 receptor expression was measured by western blotting in the 14
and 28 day PO animals and the values were normalized to GAPDH. As shown in figure
11, myocardial CB2 receptor expression was significantly increased only at 14 day time
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point in the untreated PO groups as compared to sham values. The receptor expression
levels were not significantly different as compared to the age-matched sham group in
the 28 day post pressure overload group (figure 11).
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DISCUSSION

Hypertension is a common disorder affecting a very large population, with the
numbers increasing every year and the recent statistics showing about 30% incidence
among the US population (Go et al., 2013). Prolonged and severe hypertension leads to
cardiac remodeling and an increased risk of developing heart failure. Current therapies
are only partially beneficial at preventing or reversing the adverse remodeling changes
affecting cardiac function (Gustafsson et al., 2010). Thus, there is a need for improved
therapies for preventing or attenuating the pathophysiologic changes in remodeling. The
endocannabinoid system has been recently implicated in mediating protective effects in
tissue remodeling associated with various cardiovascular disorders. However, there is a
limited knowledge base exploring the role of the ECS in cardiac remodeling secondary
to hypertension.
In the present study, we determined the expression of CB1 and CB2 receptors on
cardiac fibroblasts in the rat LV cross-sections. These receptors have been discovered
in the cardiovascular system in the recent years on human cardiomyocytes (Bonz et al.,
2003; Weis et al., 2010) and human endothelial and smooth muscle cells (Liu et al.,
2000; Rajesh et al., 2007, 2008a) but they have not been previously demonstrated
directly on cardiac left ventricular fibroblasts. Our immunohistochemistry results indicate
that both these receptors are expressed on resident cardiac fibroblasts and also on
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myocytes in the rat LV sections. CB1 expression on rat fibroblasts in the LV has been
demonstrated for the first time while expression on myocytes has been previously
reported (Mukhopadhyay et al., 2010). CB2 expression on rat fibroblasts in the LV has
also been demonstrated for the first time while expression on myocytes has been
previously reported (Lepicier et al., 2003).
Previous work has not elucidated whether the myocardial expression of CB1 and
CB2 receptors is altered in a temporal manner as the heart undergoes hypertrophic and
fibrotic changes with progressive remodeling secondary to pressure overload or
remodeling induced by hypertension. To elucidate this, we induced pressure overload
by abdominal aortic constriction (AAC) in four groups of rats (3, 5, 14 and 28 day PO)
and included groups of age-matched controls also known as sham animals (surgical
procedure without constriction of aorta). The animals were rendered hypertensive by
AAC as evidenced by an increase in the mean arterial pressure, which was significantly
higher in the 14 and 28 day PO groups as compared to their age matched controls.
Hypertrophy was apparent by significantly increased LV mass and LV/body weight index
at the 14 and 28 day time points in the PO groups. Cardiac fibroblasts cause fibrosis by
producing and depositing excessive collagen in the extracellular matrix and fibrosis is
also a major part of cardiac remodeling as previously described above. Incidence of
fibrosis was determined by measuring the total collagen content in the LV sections by
hydroxyproline analyses. Fibrosis was evident at the 14 day time point in the PO group
and also increased in the 28 day group as compared to their age matched controls. The
fibrosis was found to be progressive since the elevation in total collagen content at the
28 day time point was significantly higher as compared to that at the 14 day time point.
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In a stressed myocardium, fibroblasts secrete the chemokine, monocyte
chemoattractant protein-1 (MCP-1) (Behr et al., 2000; Manabe et al., 2002), which
stimulates the production of profibrotic cytokine and growth factors that stimulate the
fibroblasts in an autocrine and paracrine manner to produce collagen. Under
pathological stimuli, MCP-1 expression is also induced in the endothelial cells, which
can cause immune cell infiltration and release of proinflammatory and profibrotic factors
such as TNF-α, TGF-β and PDGF, which stimulate hypertrophic and fibrotic responses
(Dobaczewski and Frangogiannis, 2010). The AAC induced pressure overload model
causes extensive remodeling of myocytes and the ECM. However, it only shows an
initial transient inflammatory response and does not lead to oxidative stress, a
prolonged infiltration of inflammatory cells and loss of myocytes such as that seen in
models of ischemia and infarction. A study by Higashiyama et al. (2007) demonstrated
an intense initial infiltration of macrophages and neutrophils on day 3 after induction of
pressure overload, which had declined thereafter by day 10. Our study showed an
elevation in MCP-1 levels at day 3 post induction of pressure overload in the initial
inflammatory phase and a decline thereafter by day 5. This effect was similar to the
previous study by Kuwahara et al. (2004) showing peak MCP-1 mRNA expression at
day 3 post induction of pressure overload in rats with a subsequent decline after day 3.
Thus, in agreement with previous work, MCP-1 was induced in the initial inflammatory
phase for recruitment of macrophages and neutrophils in the myocardium.
Studies have implicated the endocannabinoid system in cardiac remodeling
associated with ischemia and cardiomyopathy, with CB1 receptor antagonists and CB2
receptor agonists linked to beneficial effects. We measured the myocardial CB1 and
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CB2 receptor temporal expression at 3, 5, 14 and 28 day time points post induction of
pressure overload. CB1 receptor expression was increased significantly at the 3 day
time point in PO animals after which there was a downward trend in expression and the
expression at 5 days in the PO group was unchanged from that in age-matched sham
animals. The downward trend of CB1 expression continued further and CB1 receptor
levels were significantly decreased at 14 and 28 days in the PO groups as compared to
age-matched sham values. Myocardial CB2 protein level was significantly increased at
the 3, 5 and 14 day time points in the untreated PO groups as compared to agematched sham values. Subsequently, myocardial CB2 receptor expression was similar
to age-matched sham levels at the 28 day time point. Thus, myocardial CB1 and CB2
receptors seem to be temporally altered in cardiac remodeling induced by pressure
overload.
Previous studies have shown CB1 receptor antagonism to be protective against
various cardiovascular disease states (Mukhopadhyay et al., 2007; Rajesh et al., 2008;
Dol-Gleizes et al., 2009, Slavic et al., 2013). CB1 antagonists were shown to have a
protective effect against myocardial infarction with reduction in infarct size on treatment
with rimonabant, a synthetic CB1 antagonist (Lim et al., 2009). Mukhopadhyay and
group (2010) have demonstrated reduced levels of collagen and profibrotic factors in
CB1 null mice in a model of doxorubicin induced oxidative stress and fibrosis. CB1
antagonism and CB1 knockout animal models have also been shown to exert beneficial
effects in hepatic fibrosis (Chen et al., 2012; Giannon et al., 2012). Contradictory
findings also exist showing adverse effects of CB1 antagonism (Wagner et al., 2003;
Mendizabal and Graschinsky, 2007). A recent study by Liao et al., 2012 showed
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deletion of CB1 receptors promoting cardiac remodeling via activation of epidermal
growth factor receptor and MAP kinases. More studies are needed to delineate the full
effects of modulating the CB1 receptors in cardiovascular pathology, though majority of
the studies tend towards blockade of CB1 receptors showing beneficial effects. We can
speculate that the temporal decrease in CB1 receptor expression at the 14 and 28 day
time points found in our study could be in agreement with the protective effects of CB1
antagonism and could be a physiological response of the remodeling heart to limit the
adverse pathological changes. The transient increase in CB1 expression at 3 days
before it began the downward trend could be attributed to the initial inflammatory phase
after induction of pressure overload seen in our model. Studies have shown that CB1
receptors are expressed on immune cells, although to a lesser extent than CB2
receptors, and they play a role in immune cell modulation (Kaplan, 2013).
CB2 receptor activation has been shown to mediate cardioprotective effects in
ischemia and reduction of infarct size (Lepicier et al., 2003). A study by Di Fillipo et al.
(2004) with WIN-55212-2 (non-specific CB1 and CB2 agonist) showed a reduction in
reperfusion injury and infarct size as well as decreased activation of macrophages and
local generation of cytokines. Further, this beneficial effect was blocked by a specific
CB2 antagonist (Di Fillipo et al., 2004). CB2 receptor activation has also demonstrated
beneficial effects in counteracting hepatic fibrosis (Julien et al., 2005; Munoz-Luque et
al., 2008). Evidence shows CB2 receptors can limit post-ischemic fibrosis (Defer et al.,
2009). In our current study, CB2 receptor expression could be increased on the
fibroblasts at the 3, 5 and 14 day time points to limit the extent of fibrosis. Another
possibility to consider is that the increase in expression seen at 3 and 5 days could be
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contributed by the initial influx of immune cells in our model as CB2 receptors are
known to be widely expressed on different types of immune cells (Miller and Stella,
2008).

CONCLUSION

The present study shows that CB1 and CB2 receptors are expressed on cardiac
fibroblasts as demonstrated in rat LV cross-sections. The expression of these receptors
is also seen on rat cardiac myocytes in agreement with previous work showing their
existence on myocytes (Bonz et al., 2003; Lepicier et al., 2003). The CB1 receptor
expression is altered temporally in the PO animals with the expression transiently going
up at 3 days and then significantly decreasing at the 14 and 28 day time points. The
CB2 receptor expression is also altered temporally in the PO animals with the
expression markedly increasing at the initial 3 and 5 day time points, possibly in
response to the initial inflammatory response in the PO model. CB2 receptor
expression is also found to be up at the 14 day time point in the PO animals while
returning to control levels by day 28. The temporal alterations in CB1 and CB2
receptors in cardiac remodeling are an interesting finding, which demonstrates that the
ECS is responsive to pathophysiological changes associated with pressure overload
induced cardiac remodeling.
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AIM 2

Aim 2: To determine the effects of CB1 cannabinoid receptor modulation on
human ventricular fibroblasts (HVF).
Aim 2.1: To determine expression of CB1 receptors on HVF
Aim 2.2: To measure changes in total collagen and expression of collagen type 1A and
type 3A after treatment of CB1 antagonist, AM251.
Aim 2.3: To determine levels of MCP-1 after treatment of CB1 antagonist, AM251

Rationale:
Studies have established that blockade of CB1 receptors can prevent fibrosis in
the heart in doxorubicin induced cardiomyopathy (Mukhopadhyay et al., 2010; Slavic et
al., 2013) and in the liver (Patsenkar et al., 2011; Giannon et al., 2012). CFs are the
primary cells involved in fibrosis and ECM remodeling. Although CFs are stimulated by
numerous neurohormonal chemicals, vasoactive peptides and cytokines which affect
their downstream activities promoting fibrosis, the role of the endocannabinoid system
in promoting this deleterious remodeling is uncertain (Weber et al., 1994; Segura et al.
2012). Expression of CB1 receptors have been shown in various cell types of the heart
(Bonz et al., 2003; Rajesh et al., 2008; Liu et al., 2000), but to date, expression of these
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receptors on human ventricular fibroblasts (HVF) has not been documented and the
effects of modulating the activities of CB1 receptors directly on the HVF remain to be
elucidated. We hypothesize that CB1 receptors are expressed on human ventricular
fibroblasts and that antagonism of the CB1 receptors would have an antifibrotic effect.

Experimental Approach:
Human ventricular fibroblasts (HVF) were grown to 80% confluence in 100 mm
cell culture plates in DMEM with 10% FBS and 5% NCS. Cells were serum starved for
24 hours with DMEM containing 2% FBS before treatment with 2-arachidonoyl glycerol
(2-AG) (endocannabinoid agonist), the synthetic CB1 antagonist, AM251, or a
combination of 2-AG+AM251. These treatments were carried out for 48 hours with redosing after 24 hours. Fibroblasts were stimulated with 2-AG, 30 minutes after
treatment with AM251 in the combined treatment group. Each treatment was performed
in triplicate in two independent studies. The culture media was collected from all the
plates at the end of the treatment for determination of total secreted collagen and MCP1. Cell lysates were obtained for protein quantification. For qPCR studies, HVF were
grown to 80% confluence in 60 mm cell culture dishes in DMEM with 10% FBS and 5%
NCS. Cells were serum starved for 24 hours with DMEM containing 2% FBS before
treatment with 2-AG and AM251. Each treatment was performed in triplicate in two
independent experiments. Cell lysates were prepared, RNA was extracted using the
RNeasy Mini kit (Qiagen, Valencia, CA) and qPCR was performed on each RNA sample
in duplicate in two independent experiments for measuring mRNA levels of collagen 1A
and 3A. FAM labeled TaqMan collagen 1A1 (ref no. Hs00164004_m1) and collagen
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3A1 (ref no. Hs00943809_m1) primers and VIC labeled TaqMan GAPDH primer (ref no.
Hs02758991_g1) from Applied Biosystems (Grand Island, NY) were used for qPCR
studies. The different groups and drug concentrations for all of the above experiments
are outlined below in table 3. Immunofluorescence was performed on HVF fixed on 8chamber slides for determining the expression of CB1 receptors using a rabbit
polyclonal anti-CB1 primary antibody (1:100 in 1% BSA in PBS) (Thermo Scientific,
Rockford, IL) and Alexafluor 488 labeled goat anti-rabbit secondary antibody (1:500 in
1% BSA in PBS) (Molecular Probes, Grand Island, NY).

Table 3: Treatment groups for CB1 antagonism studies on HVF

Drugs

Doses

Control

Untreated

Vehicle (Ethanol)

10 uM

2- Arachidonoyl glycerol (2-AG)

10 uM

AM251

10 uM

2-AG + AM251

10 uM + 10 uM
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RESULTS

Figure 12: Expression of CB1 receptors on human ventricular fibroblasts.

(A)
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(B)

Figure 12: (A) Expression of CB1 receptors on human ventricular fibroblasts. CB1
receptors were detected by using rabbit anti-CB1 antibody and Alexafluor 488 labeled
goat anti-rabbit secondary antibody. Nuclei were counterstained with DAPI. (B)
Negative control for CB1 receptors where anti-CB1 primary antibody was omitted and
only Alexafluor 488 labeled secondary antibody was used. Nuclei were counterstained
with DAPI.

Expression of CB1 receptors on human ventricular fibroblasts was determined by
fluorescence microscopy using a rabbit polyclonal anti-CB1 primary antibody and
Alexafluor 488 labeled goat anti-rabbit secondary antibody. As seen in figure 12(A),
CB1 receptors were apparently expressed on the membranes of the human ventricular
fibroblasts. The nuclei were counterstained blue using DAPI (4,6- diamidino-2phenylindole). The absence of non-specific binding of the secondary antibody was
confirmed by obtaining a negative control without the use of the anti-CB1 primary
antibody and using only the fluorescent secondary antibody [figure 12(B)].
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Figure 13: Detection of CB1 receptors on human ventricular fibroblasts by
Western Blotting

Fibroblast cell lysates

Positive
control

Figure 13: Representative western blot showing expression of CB1 receptors on
human ventricular fibroblasts. Cell lysates constituting 40 ug of protein/well were
loaded and analyzed using rabbit polyclonal anti-CB1 antibody. Positive control used
was mouse hippocampus.

The presence of CB1 receptors on human ventricular fibroblasts was also
determined by detection with the anti-CB1 primary antibody using western blots as
shown in figure 13. Each lane was loaded with 40 ug of protein using fibroblast cell
extracts. A band specific for the CB1 receptor was detected at approximately 60 kD.
The positive control used was mouse hippocampus, which is known to have an
abundance of CB1 receptors (Pacher et al., 2006).
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Figure 14: Total collagen secreted by fibroblasts is altered by CB1 antagonist
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Figure 14: Total collagen secreted in the culture media by human ventricular
fibroblasts measured by hydroxyproline analysis on treatment with 2-AG (10uM),
AM251 (10uM) and 2-AG + AM251 (both 10uM). Values are represented as mean ±
SEM where *p ≤ 0.05, **p ≤ 0.01 as compared to the respective vehicle control and
##p<0.01 as compared to 2-AG.

Total collagen secreted by human ventricular fibroblasts into the culture media
was determined by assessing the hydroxyproline concentration. Total collagen secreted
was significantly increased by 2-AG treatment as compared to the vehicle control (figure
14). Treatment with the CB1 antagonist, AM251, by itself significantly decreased the
total collagen secreted as compared to the vehicle control as well as compared to 2-AG
alone. However, this decrease was not seen when fibroblasts were co-treated with 2AG + AM251 as compared to the vehicle or 2-AG alone (figure 14).
63

Figure 15: Collagen 1A and 3A expression is responsive to CB1 antagonist
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Figure 15: (A) Collagen 1A and (B) collagen 3A mRNA expression in 2-AG (10uM),
AM251 (10uM) and 2-AG + AM251 (both 10uM) treated human ventricular fibroblasts
normalized to their respective vehicles as measured by qPCR. Values represented as
mean ± SEM where ***p ≤ 0.001 as compared to the vehicle control for AM251 and ^ p
≤ 0.05 as compared to vehicle control for 2-AG.
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mRNA expression of Collagen 1A and 3A in human ventricular fibroblasts following drug
treatments was determined by quantitative real time PCR analyses. There was a
significant difference between collagen 1A mRNA expression obtained after treatment
with AM251 and 2-AG+AM251 [figure 15(A)]. As seen in figure 15(B), collagen 3A
mRNA expression was significantly decreased by 2-AG treatment as compared to the
vehicle control. Treatment with the CB1 antagonist, AM251, significantly decreased
collagen 3A mRNA expression as compared to the vehicle control. This decrease was
also seen when the fibroblasts were co-treated with 2-AG + AM251 as compared to the
vehicle control [figure 15(B)].
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Figure 16: MCP-1 secreted by fibroblasts is altered by AM251 treatment
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Figure 16: MCP-1 (ng/mg of protein) secreted in the culture media by human ventricular
fibroblasts on treatment with 2-AG (10uM), AM251 (10uM) and 2-AG + AM251 (both 10uM)
measured by ELISA. Values are represented as mean ± SEM where *p ≤ 0.05, ***p ≤ 0.001 as
compared to the vehicle control and ####p<0.001 as compared to 2-AG.

MCP-1 secreted in the culture media by human ventricular fibroblasts was
analyzed by a commercially available ELISA kit. MCP-1 secreted in the media was
significantly increased by 2-AG as compared to the vehicle control as seen in figure 16.
Treatment of fibroblasts with CB1 antagonist, AM251, as well as with co-treatment of 2AG + AM251 significantly decreased the amount of MCP-1 secreted in the media as
compared to the vehicle control. There was also a significant decrease in MCP-1 levels
obtained by combined treatment with 2-AG + AM251 as compared to those obtained by
treating with 2-AG alone (figure 16).
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DISCUSSION

The endocannabinoid system is a ubiquitous system involved in functions of
various organs of the body (Pacher et al., 2006). It was found to be active in the
cardiovascular system only recently and subsequent research has implicated it in
pathophysiological conditions of this system. Studies have shown involvement of the
CB1 and CB2 receptors as well as some novel putative cannabinoid receptors in the
observed cardiovascular effects (Pacher and Steffens, 2009). Previously, CB1 receptors
were found to be mainly abundant in the brain and they have been identified in the heart
and vasculature only in the past decade. A few recent studies have shown their
existence in the different components of the cardiac system such as in human atrial
myocytes (Bonz et al., 2003), human cardiac myocytes (Mukhopadhyay et al., 2010),
human coronary artery smooth muscle cells (Rajesh et al., 2008a) and vascular
endothelial cells (Liu et al., 2000) and whole myocardial tissue extracts (Wagner et al.,
2003). Here, we have shown the presence of CB1 receptors on human ventricular
fibroblasts under basal conditions. CB1 receptors were detected by
immunofluorescence using rabbit anti-CB1 polyclonal antibody and the binding to these
receptors was confirmed when there was no signal reported in the negative control
wherein the use of anti-CB1 antibody was omitted. As previously stated above, cardiac
fibroblasts are the primary cells of the ECM involved in maintaining homeostasis of the
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ECM and collagen remodeling in fibrotic processes. Collagen is the fundamental
substance constituting the extracellular matrix in the heart and mainly consists of two
major types, collagen 1 and 3, along with several other minor subtypes (Porter et al.,
2009). Excessive collagen production and deposition by cardiac fibroblasts under
various pathological stimuli such as hypertension, ischemia and myopathy leads to
fibrosis in the extracellular matrix, eventually making the ventricular walls stiffer and
affecting cardiac function (Segura et al. 2012; Sullivan and Black, 2013). However,
studies to date have not detailed the effects of directly modulating the CB1 receptors on
human ventricular fibroblasts and effects on collagen production and the chemokine,
MCP-1, which stimulates profibrotic factors.
In the present study, we investigated the effects of CB1 antagonism on the total
collagen secreted by HVF. Total collagen secreted in the media by the cells was
measured by the hydroxyproline content. An increase in total collagen secretion was
seen following treatment with the endocannabinoid agonist, 2-AG. The CB1 antagonist,
AM251, significantly decreased the total collagen levels as compared to the vehicle
control but not when co-treated with 2-AG. Since blocking the CB1 receptors by AM251
caused a decrease in production and secretion of collagen by HVF, CB1 receptors thus
seem to be involved in having a profibrotic effect on collagen synthesis. This effect of
CB1 antagonism might translate in to a beneficial effect against excessive collagen
production and deposition in a model of cardiovascular fibrosis. The observed antifibrotic effect of blocking CB1 receptors on HVF is in agreement with a study by
Mukhopadhyay and group (2010) that demonstrated reduced levels of collagen and
profibrotic factors such as TGF-β and fibronectin in CB1 null mice in a model of
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doxorubicin induced oxidative stress and fibrosis. A recent study has also shown CB1
antagonism by rimonabant to be protective against post ischemic fibrosis and
remodeling by reducing the accumulation of collagen in a rat model of myocardial
ischemia and infarction (Slavic et al., 2013). Moreover, numerous studies have
demonstrated anti-fibrotic effects of CB1 receptor antagonism in liver fibrosis by
reversal of developed fibrosis (Patsenkar et al., 2011; Giannon et al., 2012) or
knockdown of CB1 receptors preventing activation and production of ECM proteins by
hepatic stellate cells (HSCs) (Teixeira-Clerc et al., 2006; Chen et al., 2012). Hepatic
stellate cells are analogous to cardiac fibroblasts under fibrotic conditions wherein they
are involved in ECM remodeling (Moreira, 2007). CB1 receptor blockade is also known
to be beneficial in reducing fibrosis in systemic sclerosis (Palumbo-Zerr et al., 2012) and
diabetic cardiomyopathy (Rajesh et al., 2012). In our study, the reason for not seeing
the decrease in collagen on co-treatment of AM251 with 2-AG is not clear at this point,
but it could possibly be due to involvement of receptors other than CB1 stimulated by 2AG such as the novel cannabinoid receptors or GPR55 (Begg, 2005; Okuno and
Yokomizo, 2011).
The effect of CB1 antagonism on the gene expression of collagen 1A and 3A was
determined by qPCR. Fibroblasts treated with 2-AG by itself showed significant
reduction in collagen 3A mRNA levels and also a significant reduction on treatment with
AM251. The expression of collagen 3A was attenuated by AM251 even after stimulation
with 2-AG in the combined treatment group. These results suggest that CB1
antagonism is involved in reducing the expression of collagen 3A and this decrease
may have contributed to the reduction in total collagen levels seen with AM251. In case
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of 2-AG, the total collagen was increased while the collagen 3A expression was
decreased and collagen 1A expression was not significantly altered by 2-AG itself.
These conflicting results could be due to the fact that collagen mRNA levels were
measured at 24 hours while the total collagen protein levels were determined at 48
hours. The decrease in mRNA levels of collagen 3A could be a transient event while
collagen 1A may be altered at a later time point, which could contribute to the increased
total collagen protein seen at 48 hours. Collagen 1A levels were significantly reduced by
stimulation of the cells with 2-AG after blockade of CB1 receptors with AM251 as
compared to those obtained with just AM251 treatment. This could indicate a role of
CB2 receptors causing a decrease in collagen 1A after stimulation with 2-AG, since 2AG is an agonist at both CB1 and CB2 receptors.
Alterations in gene expression of collagen 1A and 3A in cardiac fibroblasts by CB1
antagonism have not been studied before. Previous studies on hepatic fibrosis have
shown CB1 blockade to downregulate mRNA expression of procollagen 1A in hepatic
stellate cells (Patsenkar et al., 2012) and reduced expression of collagen 1A in the liver
(Giannone et al., 2012).
MCP-1 is a chemokine stimulating profibrotic factors and can induce collagen
production by cardiac fibroblasts (Dobaczewski and Frangogiannis, 2010). We
measured MCP-1 secreted in the culture media after treatment of HVF with AM251.
MCP-1 was found to be significantly elevated by treatment of 2-AG alone. This increase
could possibly have lead to the increased total collagen secretion seen with 2-AG.
Treatment with AM251 robustly decreased the amount of MCP-1 secreted by HVF. The
decrease in MCP-1 levels was maintained on treatment of AM251 even after HVF were
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stimulated by 2-AG in the combined treatment group. Our results conform to previous
studies showing decrease in MCP-1 expression by CB1 blockade or knockdown in
HSCs or hepatic fibrosis models (Trebicka et al, 2011; Giannone et al., 2012) which was
associated with an anti-fibrotic effect. Thus, antagonism of CB1 receptors seems to be
anti-fibrotic and the decrease in total collagen and collagen 3A expression could be a
downstream effect of the reduced MCP-1 production by AM251. MCP-1 has been
shown to directly stimulate TGF-β1 production by lung fibroblasts, which can affect their
collagen production (Gharaee-Kermani et al., 1996). A study by Slavic et al. (2013)
showed that CB1 antagonism by rimonabant dose-dependently prevented increase in
TGF- β expression induced by IL-1 in cardiac fibroblasts and TGF-b expression was
also found to be reduced in CB1 null mice (Mukhopadhyay et al., 2010). Given those
previous reports by others, we speculate that CB1 induced reduction in MCP-1 could
decrease expression and activation of the profibrotic factor, TGF-β, in HVF to affect
their collagen production. TNF-α is another important profibrotic factor involved in
promoting collagen production (Duerrschmid et al., 2013). CB1 blockade has been
shown to reduce expression of TNF-alpha in hepatic fibrosis (Trebicka et al, 2011;
Giannone et al., 2012), which could also contribute to the anti-fibrotic effect seen with
HVF.
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CONCLUSION

To the best of our knowledge, expression of CB1 receptors was demonstrated for
the first time on HVF by immunofluorescence and western blotting. CB1 antagonism
reduced total collagen secretion and expression of collagen 3A by HVF. Blockade of
CB1 receptors also decreased the amount of MCP-1, secreted in the culture media.
Thus, in accordance with the current literature, our results indicate that CB1 receptors
are profibrotic and CB1 antagonism could prove beneficial under fibrotic situations.
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AIM 3

Aim 3: To determine the effects of CB2 cannabinoid receptor modulation on
human ventricular fibroblasts (HVF).
Aim 3.1: To determine expression of CB2 receptors on HVF
Aim 3.2: To measure changes in total collagen and expression of collagen type 1A and
type 3A after treatment of CB2 antagonist, AM630.
Aim 3.3: To determine levels of MCP-1 after treatment of CB2 antagonist, AM630

Rationale:
Previous work has established that cannabinoids acting via CB2 receptors can
prevent fibrosis in the heart post ischemia (Defer et al.2009) as well as in other
tissues such as liver (Munoz-Luque et al., 2008) and pancreas (Michalski et al.,
2008). CB2 receptors have been previously shown to be expressed in the heart
(Rajesh et al., 2007; Weis et al. 2010). However, to date, expression of CB2
receptors has not been demonstrated on HVF and it is uncertain whether any
cardioprotective effects of CB2 receptors against fibrosis are mediated through
cardiac fibroblasts. We hypothesize that CB2 receptors are involved in mediating a
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beneficial effect against fibrosis and antagonism of the CB2 receptors expressed on
HVF would prove to be profibrotic.

Experimental Approach:
Human ventricular fibroblasts (HVF) were grown to 80% confluence in 100 mm
cell culture plates in DMEM with 10% FBS and 5% NCS. Cells were serum starved for
24 hours with DMEM containing 2% FBS before treatment with 2-arachidonoyl glycerol
(2-AG) (endocannabinoid agonist), synthetic CB2 antagonist, AM630, or a combination
of 2-AG+AM630. These treatments were carried out for 48 hours with re-dosing after 24
hours. Fibroblasts were stimulated with 2-AG, 30 minutes after treatment with AM630 in
the combined treatment group. Each treatment was performed in triplicate in two
independent studies. The culture media was collected from all the plates at the end of
the treatment for determination of total collagen and MCP-1. Cell lysates were obtained
for protein quantification. For qPCR studies, HVF were grown to 80% confluence in 60
mm cell culture dishes in DMEM with 10% FBS and 5% NCS. Cells were serum starved
for 24 hours with DMEM containing 2% FBS before treatment with 2-AG and AM630.
Each treatment was performed in triplicate in two independent experiments. Cell lysates
were prepared for RNA extraction and qPCR was performed on each RNA sample in
duplicate in two independent experiments for measuring mRNA levels of collagen 1A
and 3A. FAM labeled TaqMan collagen 1A1 (ref no. Hs00164004_m1) and collagen
3A1 (ref no. Hs00943809_m1) primers and VIC labeled TaqMan GAPDH primer (ref no.
Hs02758991_g1) from Applied Biosystems (Grand Island, NY) were used for qPCR
studies. The different groups and drug concentrations for all of the above experiments
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are outlined below in table 4. Immunofluorescence was performed on HVF fixed on 8chamber slides for determining the expression of CB2 receptors using a rabbit
polyclonal anti-CB2 primary antibody (1:100 in 1% BSA in PBS) (Thermo Scientific,
Rockford, IL) and Alexafluor 488 labeled goat anti-rabbit secondary antibody (1:500 in
1% BSA in PBS) (Molecular Probes, Grand Island, NY)

Table 4: Treatment groups for CB2 antagonism studies on HVF

Drugs

Doses

Control

Untreated

Vehicle for 2-AG (Ethanol)

10 uM

Vehicle for AM630 (DMSO)

10 uM

2- Arachidonoyl glycerol (2-AG)

10 uM

AM630

10 uM

2-AG + AM630

10 uM + 10 uM
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RESULTS

Figure 17: Expression of CB2 receptors on human ventricular fibroblasts

(A)
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(B)

Figure 17: (A) Expression of CB2 receptors on human ventricular fibroblasts. CB2
receptors were detected by using rabbit anti-CB2 antibody and Alexafluor 488 labeled goat
anti-rabbit secondary antibody. Nuclei were counterstained with DAPI. (B) Negative control
for CB2 receptors where anti-CB2 primary antibody was omitted and only Alexafluor 488
labeled secondary antibody was used. Nuclei were counterstained with DAPI.

Expression of CB2 receptors on human ventricular fibroblasts was determined by
fluorescence microscopy using a rabbit polyclonal anti-CB2 primary antibody and
Alexafluor 488 labeled goat anti-rabbit secondary antibody. Figure 17(A) show an
apparent expression of CB2 receptors on the membranes of the human ventricular
fibroblasts. The nuclei were counterstained blue using DAPI. A negative control was
obtained using only the fluorescent secondary antibody and omission of the anti-CB2
primary antibody to ensure the absence of non-specific binding of the secondary
antibody (figure 17B).
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Figure 18: Detection of CB2 receptors on the human ventricular fibroblasts by
Western Blotting

Fibroblast cell lysates

Positive
control

Figure 18: Representative western blot showing expression of CB2 receptors on
human ventricular fibroblasts. Cell lysates constituting 40 ug of protein/well were
loaded and analyzed using rabbit polyclonal anti-CB2 antibody. Positive control used
was mouse hippocampus.

The presence of the CB2 receptors on the human ventricular fibroblasts was also
determined by detection with the anti-CB2 primary antibody in western blots as shown
in figure 18. Each lane was loaded with 40 ug of protein using fibroblast cell extracts. A
band specific for the CB2 receptor was detected at approximately 40 kD. The positive
control used here was mouse hippocampus, which is known to express CB2 receptors
(Pacher et al., 2006)
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Total Collagen Content
(Hydroxyproline; ug/mg of dry weight)

Figure 19: Total collagen secreted by fibroblasts is altered by CB2 antagonist
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Figure 19: Total collagen secreted in the culture media by human ventricular fibroblasts
was measured by hydroxyproline analysis on treatment with 2-AG (10uM), AM630
(10uM) and 2-AG + AM630 (both 10uM). Values are represented as mean ± SEM where
*p ≤ 0.05, **p ≤ 0.01 and ****P ≤ 0.001 as compared to the respective vehicle control.

Total collagen secreted by human ventricular fibroblasts in the culture media was
determined by the hydroxyproline concentration. As seen in figure 19, total collagen
secreted was significantly increased by 2-AG treatment as compared to the vehicle
control. Treatment with CB2 antagonist, AM630, significantly increased the total
collagen secreted by fibroblasts as compared to the vehicle control. Total collagen
secreted in the media was also significantly increased when fibroblasts were co-treated
with 2-AG + AM630 and the increase seen was even higher than that with AM630
alone. There was no significant difference between levels of collagen obtained with 2AG alone and combined treatment of 2-AG + AM630 (figure 19).
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Figure 20: Collagen 1A and 3A expression is responsive to CB2 antagonist
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Figure 20: (A) Collagen 1A and (B) collagen 3A mRNA expression in 2-AG (10uM), AM630
(10uM) and 2-AG + AM630 (both 10uM) treated human ventricular fibroblasts normalized
to their respective vehicles as measured by quantitative real time PCR. Values represented
as mean ± SEM where ***p ≤ 0.001 as compared to the vehicle control for AM630 and
#### p ≤ 0.001 as compared to 2-AG.
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mRNA expression of Collagen 1A and 3A in human ventricular fibroblasts after all
the drug treatments was determined by quantitative real time PCR analyses. As seen in
figure 20(A), collagen 1A mRNA expression was not significantly different when
fibroblasts were treated with 2-AG as compared to the vehicle control. The CB2
antagonist, AM630, significantly elevated the mRNA levels of collagen 1A as compared
to the vehicle control. The mRNA levels were also significantly elevated with the
combined treatment of 2-AG + AM630 as compared to the vehicle. The expression of
collagen 1A was significantly higher when the fibroblasts were co-treated with 2-AG +
AM630 than the levels obtained with 2-AG alone. Collagen 3A mRNA levels were
unaffected by all of the above drug treatments [figure 20(B)].
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Figure 21: MCP-1 secreted by fibroblasts is altered by AM630 treatment
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Figure 21: MCP-1 (ng/mg of protein) secreted in the culture media by human ventricular
fibroblasts on treatment with 2-AG (10uM), AM630 (10uM) and 2-AG + AM630 (both 10uM)
measured by Enzyme Linked Immunosorbent Assay. Values are represented as mean ± SEM
where *p ≤ 0.05, **p ≤ 0.01 as compared to the vehicle control for AM630, ^p ≤ 0.05 as
compared to the vehicle control for 2-AG and ###p ≤ 0.001 as compared to 2-AG.

MCP-1 secreted in the culture media by human ventricular fibroblasts was
analyzed by a commercially available ELISA kit. MCP-1 secreted in the media was
elevated by 45% on treatment with 2-AG as compared to the vehicle control (figure 21).
The treatment of fibroblasts with the CB2 antagonist, AM630, caused a decrease of
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about 42% in the amount of MCP-1 secreted in the media as compared to the vehicle
control. MCP-1 secreted by the fibroblasts was also reduced by about a similar
percentage as AM630 when co-treated by 2-AG + AM630 as compared to the vehicle.
There was a significant decrease in MCP-1 levels obtained by combined treatment with
2-AG + AM630 as compared to those obtained by treating with 2-AG alone (figure 21).

83

DISCUSSION

The endocannabinoid system is well documented to play a role in various human
disorders, including cardiovascular, neuropsychological, metabolic and inflammatory
diseases (Pacher et al., 2006). This system is under extensive research for potential
new therapeutic applications in such numerous areas. In the recent years, the
endogenous (endocannabinoids) and exogenous (Δ9-THC and synthetic cannabinoid
compounds) ligands and the cannabinoid receptors have been implicated in
cardiovascular disorders such as cardiomyopathy and ischemia involving cardiac
remodeling. The CB2 receptors were initially found to be mainly expressed on immune
cells, but were subsequently found to be expressed in the brain and peripheral organ
systems (Onaivi et al., 2006; Pacher and Mechoulam, 2011). Later studies by various
groups demonstrated the expression of these receptors in the different components of
the cardiac system such as in human cardiomyocytes (Weis et al., 2010;
Mukhopadhyay et al., 2010), human coronary artery smooth muscle cells (Rajesh et al.,
2007) and vascular endothelial cells (Rajesh et al., 2008b) and rat cardiomyoblasts
(Shmist et al., 2006). Here, we have shown the presence of CB2 receptors on human
ventricular fibroblasts under basal conditions by immunofluorescence and western
blotting using rabbit anti-CB2 polyclonal antibody. Binding to these receptors in
immunofluorescence was confirmed by obtaining a negative control showing no signal
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wherein the anti-CB2 antibody was not used. However, studies to date have not
elucidated the effects of directly modulating these receptors on HVF and effects on
production of collagen and the chemokine, MCP-1.
Total collagen secreted by the HVF in culture media was measured by the
hydroxyproline content. An increase in total collagen secreted by the fibroblasts was
seen on treatment with 2-AG by itself. The total collagen levels were significantly
increased by the CB2 antagonist, AM630, and this elevation was seen even after
fibroblasts were co-treated with 2-AG + AM630. Real time PCR analyses of expression
of collagen 1A revealed that it was significantly increased by AM630 as well as by the
combined treatment of 2-AG + AM630. Also, expression levels of collagen 1A obtained
by co-treatment of 2-AG + AM630 were significantly higher than those obtained by 2-AG
alone. Type 1A is a major type of collagen present in the ECM and increase in its
expression could be the main contributor to increasing the total collagen synthesis by
AM630. These results indicate that CB2 receptors seem to be involved in reducing
collagen production and their antagonism exerts a profibrotic effect by enhancing
collagen 1A expression, total collagen synthesis and secretion by HVF.
Previous studies have established that cannabinoids can produce antifibrogenic
effects in a number of different organs via activation of CB2 receptors. CB2 activation
was found to prevent fibrosis in the heart (Defer et al.2009) as well as in the liver (Julien
et al., 2005; Munoz-Luque et al., 2008; Avraham et al., 2012), lungs and skin (Servettaz
et al., 2010) and the pancreas (Michalski et al., 2008) by decreasing collagen
production and accumulation and attenuating activation and proliferation of the HSCs in
liver fibrosis. Defer and colleagues (2009) have demonstrated protective effects of CB2
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receptors against post ischemia-reperfusion cardiac remodeling and heart failure. This
study by Defer et al. (2009) provides evidence of improved survival of myocytes and
fibroblasts in post ischemic hearts in CB2 null mice and a potential anti-fibrotic effect of
CB2 receptors by reducing production of TGF-β.
We also measured levels of the chemotaxic factor, MCP-1, secreted in the
culture media by HVF after antagonizing CB2 receptors with AM630. MCP-1 was found
to be significantly elevated by treatment of 2-AG alone. Treatment with AM630 robustly
decreased the amount of MCP-1 secreted by HVF. This decrease in MCP-1 levels was
seen on treatment with AM630 even after HVF were stimulated by 2-AG in the
combined treatment group. This indicates that CB2 receptors are involved in increasing
production and secretion of MCP-1 by HVF. MCP-1 is known to induce collagen
production and deposition (Dobaczewski and Frangogiannis, 2010). Thus, these results
suggest that CB2 receptor antagonism is profibrogenic but this effect may be
independent of MCP-1 expression. A previous study by Jbilo et al. (1999) had showed
induction of MCP-1 gene expression by CB2 receptors in human promyelocytic cell line
HL60. This effect was mediated via CB2 receptors coupled to Gi and was abolished by a
CB2 antagonist. 2-AG acting via CB2 receptors was also able to increase expression of
MCP-1 in the HL60 cell line (Kishimoto et al., 2004). Our results also show increased
levels of MCP-1 by 2-AG and this effect was reversed by both, CB1 and CB2
antagonists. On the other hand, CB2 receptor activation has been shown to be antiinflammatory and reduce the expression of MCP-1 induced by TNF in human coronary
endothelial cells and in nephropathy (Rajesh et al., 2007; Mukhopadhyay et al., 2010b).
Apparently, CB2 receptors can differently modulate MCP-1 expression in various cell
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types but the studies vary in the usage of endocannabinoids or synthetic cannabinoids
with different potencies and receptor specificities to obtain the said effects on MCP-1
(Lunn et al., 2006). Moreover, effects of CB2 receptors on immune system mediators
have been shown to go against as well as the proinflammatory way as reviewed by
Miller and Stella (2008).

CONCLUSION

In the current study, expression of CB2 receptors was demonstrated on HVF for the first
time, to the best of our knowledge. CB2 antagonism was found to increase total
collagen secreted and expression of collagen 1A by the HVF. However, blockade of
CB2 receptors decreased the amount of chemokine, MCP-1, secreted by the HVF and
hence seems to be independent of the effects seen on collagen production. Overall, in
accordance with the current literature, our results indicate that CB2 antagonism is
profibrotic and activation CB2 receptors could yield protective effects under fibrotic
situations.
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Table 5: Comparison of effects of CB1 and CB2 antagonism on HVF

Parameter

CB1 antagonism

CB2 antagonism

Total collagen
Collagen 1A

No change

Collagen 3A

No change

MCP-1

As seen in our current study, CB1 receptors seem to be involved in promoting
collagen production and having a profibrotic effect while CB2 receptors seem to be
producing an anti-fibrotic effect via reduction in collagen production. CB1 and CB2,
thus, appear to modulate collagen production in an opposing manner and the resulting
interplay between their actions seems to be one of the factors determining the levels of
collagen produced and secreted by the human ventricular fibroblasts.
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SUMMARY

The present study was designed to determine role of the endocannabinoid
system in cardiac remodeling secondary to hypertension and effects of modulation of
the cannabinoid CB1 and CB2 receptors on human ventricular fibroblasts on their
downstream fibrotic responses. Rat model of pressure overload induced by abdominal
aortic constriction was used for the in vivo study while the human ventricular fibroblast
cell line was used for the in vitro study. The presence of CB1 and CB2 receptors was
demonstrated on rat fibroblasts in left ventricular cross-sections and on human
ventricular fibroblasts for the first time. The endocannabinoid system was found to be
responsive in cardiac remodeling as the expression of CB1 and CB2 receptors was
temporally alerted as the pathological changes progressed in the rat pressure
overloaded hearts. CB1 receptor antagonism on human ventricular fibroblasts was
found to decrease their collagen expression and production, thus having an anti-fibrotic
effect while CB2 receptor antagonism was found to promote their collagen expression
and production, thus having a profibrotic effect. Our results are in accordance with
existing literature showing CB1 antagonism and CB2 agonism to be beneficial in various
cardiovascular pathologies. Modulation of these receptors could thus offer an exciting
new avenue for development of anti-fibrotic therapies and attenuating adverse
remodeling changes.
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